

10/817,328

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 AUG 10 Time limit for inactive STN sessions doubles to 40  
minutes  
NEWS 3 AUG 18 COMPENDEX indexing changed for the Corporate Source  
(CS) field  
NEWS 4 AUG 24 ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced  
NEWS 5 AUG 24 CA/CAPLUS enhanced with legal status information for  
U.S. patents  
NEWS 6 SEP 09 50 Millionth Unique Chemical Substance Recorded in  
CAS REGISTRY  
NEWS 7 SEP 11 WPIDS, WPINDEX, and WPIX now include Japanese FTERM  
thesaurus  
NEWS 8 OCT 21 Derwent World Patents Index Coverage of Indian and  
Taiwanese Content Expanded  
NEWS 9 OCT 21 Derwent World Patents Index enhanced with human  
translated claims for Chinese Applications and  
Utility Models  
NEWS 10 OCT 27 Free display of legal status information in CA/CAPLUS,  
USPATFULL, and USPAT2 in the month of November.  
NEWS 11 NOV 23 Addition of SCAN format to selected STN databases  
NEWS 12 NOV 23 Annual Reload of IFI Databases

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,  
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN customer  
agreement. This agreement limits use to scientific research. Use  
for software development or design, implementation of commercial  
gateways, or use of CAS and STN data in the building of commercial  
products is prohibited and may result in loss of user privileges  
and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 09:09:19 ON 25 NOV 2009

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

10/817,328

	ENTRY	SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 09:09:27 ON 25 NOV 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 23 NOV 2009 HIGHEST RN 1193434-24-0  
DICTIONARY FILE UPDATES: 23 NOV 2009 HIGHEST RN 1193434-24-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.


Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10817328NEW2.str



```

chain nodes :
8 9 11 19 20 21 22 23 24 25 26 27 28 30 36 37 39
ring nodes :
1 2 3 4 5 6 12 13 14 15 16 17
chain bonds :
2-11 3-9 4-19 6-8 11-12 20-21 20-22 23-24 23-25 26-37 27-30 27-36
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17
exact/norm bonds :
2-11 3-9 4-19 6-8 11-12 26-37 27-30 27-36
exact bonds :
20-21 20-22 23-24 23-25
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17
isolated ring systems :
containing 1 : 12 :

```

10/817,328

G1:CH3,H

G2:[\*1],[\*2],[\*3],[\*4],[\*5]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:CLASS 9:CLASS 11:CLASS 12:Atom  
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 19:Atom 20:CLASS 21:CLASS 22:CLASS  
23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:Atom 30:CLASS 36:CLASS  
37:CLASS 39:CLASS 40:Atom

Generic attributes :

28:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Number of Hetero Atoms : Exactly 1

Type of Ring System : Monocyclic

Element Count :

Node 28: Limited

N,N1

O,O0

S,S0

C,C5

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 09:09:54 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 11419 TO ITERATE

17.5% PROCESSED 2000 ITERATIONS

4 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 221975 TO 234785

PROJECTED ANSWERS: 170 TO 742

L2 4 SEA SSS SAM L1

=> d l4

L4 NOT FOUND

The L-number entered has not been defined in this session, or it  
has been deleted. To see the L-numbers currently defined in this


10/817,328

session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> d 12

10/817,328

L2 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 1160703-65-0 REGISTRY  
ED Entered STN: 02 Jul 2009  
CN 4-Pyrimidinamine, N-[4-(trifluoromethoxy)phenyl]-6-[2-[[4-(trifluoromethoxy)phenyl]amino]-1H-imidazol-1-yl]- (CA INDEX NAME)  
MF C21 H14 F6 N6 O2  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

10/817,328

=> 3


3 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=> d 12

10/817,328

L2 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 1160703-65-0 REGISTRY  
ED Entered STN: 02 Jul 2009  
CN 4-Pyrimidinamine, N-[4-(trifluoromethoxy)phenyl]-6-[2-[[4-(trifluoromethoxy)phenyl]amino]-1H-imidazol-1-yl]- (CA INDEX NAME)  
MF C21 H14 F6 N6 O2  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)




10/817,328

=> d 12 1-4

10/817,328

L2 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 1160703-65-0 REGISTRY  
ED Entered STN: 02 Jul 2009  
CN 4-Pyrimidinamine, N-[4-(trifluoromethoxy)phenyl]-6-[2-[[4-(trifluoromethoxy)phenyl]amino]-1H-imidazol-1-yl]- (CA INDEX NAME)  
MF C21 H14 F6 N6 O2  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

10/817,328


L2 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 957501-99-4 REGISTRY  
ED Entered STN: 11 Dec 2007  
CN 1H-Pyrazole-4-carboxylic acid, 5-ethyl-1-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-, methyl ester (CA INDEX NAME)  
MF C18 H16 F3 N5 O3  
SR Other Sources  
Database: Specs  
LC STN Files: CHEMCATS



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/817,328

L2 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 885111-17-1 REGISTRY  
ED Entered STN: 22 May 2006  
CN 4-Pyrimidinamine, 6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)  
MF C19 H14 F3 N3 O2  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

10/817,328

L2 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2009 ACS on STN  
RN 778273-48-6 REGISTRY  
ED Entered STN: 10 Nov 2004  
CN 4-Morpholineethanamine, N-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-2-pyridinyl]- (CA INDEX NAME)  
MF C22 H23 F3 N6 O2  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

10/817,328

=> s l1 sss ful  
FULL SEARCH INITIATED 09:10:58 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 229642 TO ITERATE

100.0% PROCESSED 229642 ITERATIONS 368 ANSWERS  
SEARCH TIME: 00.00.06

L3 368 SEA SSS FUL L1

=> fila caplus  
FILA IS NOT A RECOGNIZED COMMAND  
The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	199.14	199.36

FILE 'CAPLUS' ENTERED AT 09:11:22 ON 25 NOV 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Nov 2009 VOL 151 ISS 22  
FILE LAST UPDATED: 24 Nov 2009 (20091124/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

During November, try the new LSUS format of legal status information in the CA/CAPLUS family databases for free! Complete details on the number of free displays and other databases participating in this offer appear in NEWS 10.

=> s l3  
L4 25 L3  
=> d l4 1-25 bib hitstr

10/817,328

10/817,328

L4 ANSWER 1 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 2009:885621 CAPLUS  
DN 151:189956  
TI Compositions and methods for treating antitumor resistant cancers using a combination of a ATP-competitive BCR-ABL inhibitor and a non-ATP BCR-ABL inhibitor  
IN Adrian, Francisco; Dierks, Christine; Gray, Nathanael S.; Warmuth, Markus  
PA IRM LLC, Bermuda  
SO PCT Int. Appl., 56pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009091476	A1	20090723	WO 2008-US87344	20081218
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2008-21008P P 20080114


OS MARPAT 151:189956

IT 778270-11-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(GNF 2; compns. and methods for treating antitumor resistant cancers using a combination of a ATP-competitive BCR-ABL inhibitor and a non-ATP BCR-ABL inhibitor)

RN 778270-11-4 CAPLUS

CN Benzamide, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



IT 778277-15-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(GNF-5; compns. and methods for treating antitumor resistant cancers using a combination of a ATP-competitive BCR-ABL inhibitor and a non-ATP BCR-ABL inhibitor)

RN 778277-15-9 CAPLUS

CN Benzamide, N-(2-hydroxyethyl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



10/817,328




IT 778269-90-2 778270-03-4 778270-17-0  
778270-47-6 778270-68-1 778270-96-5  
778272-04-1 778272-35-8 778272-59-6  
778272-66-5 778273-43-1 778274-34-3  
778274-81-0 778276-83-8 778277-37-5  
778279-08-6 1173934-18-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(comps. and methods for treating antitumor resistant cancers using a  
combination of a ATP-competitive BCR-ABL inhibitor and a non-ATP  
BCR-ABL inhibitor)


RN 778269-90-2 CAPLUS

CN 4-Pyrimidinamine, 6-(4-pyridinyl)-N-[4-(trifluoromethoxy)phenyl]- (CA  
INDEX NAME)




RN 778270-03-4 CAPLUS

CN 4-Pyrimidinamine, 6-[3-(methylsulfonyl)phenyl]-N-[4-  
(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 778270-17-0 CAPLUS


CN 4-Pyrimidinamine, 6-(3-aminophenyl)-N-[4-(trifluoromethoxy)phenyl]- (CA  
INDEX NAME)



RN 778270-47-6 CAPLUS


CN 4-Pyrimidinamine, 6-(1H-imidazol-1-yl)-N-[4-(trifluoromethoxy)phenyl]-  
(CA INDEX NAME)

10/817,328




RN 778270-68-1 CAPLUS

CN Benzenesulfonamide, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778270-96-5 CAPLUS

CN 4-Pyrimidinamine, 6-(4-morpholinyl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 778272-04-1 CAPLUS

CN 4-Pyrimidinamine, 6-(3-pyridinyl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 778272-35-8 CAPLUS

CN 4-Pyrimidinamine, 6-(4-pyridinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 778272-59-6 CAPLUS

CN 4-Pyrimidinamine, 2-methyl-6-(4-pyridinyl)-N-[4-(trifluoromethoxy)phenyl]-


10/817,328

(CA INDEX NAME)




RN 778272-66-5 CAPLUS

CN 4-Pyrimidinamine, 5-methyl-6-(4-pyridinyl)-N-[4-(trifluoromethoxy)phenyl]-  
(CA INDEX NAME)




RN 778273-43-1 CAPLUS

CN Ethanol, 2-[[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-2-pyridinyl]amino]- (CA INDEX NAME)




RN 778274-34-3 CAPLUS

CN Methanone, 4-morpholinyl[3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)



RN 778274-81-0 CAPLUS


CN Benzamide, 4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



10/817,328


RN 778276-83-8 CAPLUS

CN Benzamide, 4-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-2-pyridinyl]- (CA INDEX NAME)




RN 778277-37-5 CAPLUS

CN Benzamide, N-methyl-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778279-08-6 CAPLUS

CN Benzamide, N-[2-(4-morpholinyl)ethyl]-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 1173934-18-3 CAPLUS

CN Benzamide, N-3-pyridinyl-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/817,328

L4 ANSWER 2 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 2009:702995 CAPLUS  
DN 151:49314  
TI Small molecule myristate inhibitors of bcr-abl and methods of use  
IN Gray, Nathanael S.; Zhang, Jianming; Okram, Barun; Deng, Xianming; Chang,  
Jaewon; Wojciechowski, Amy  
PA Dana Farber Cancer Institute, USA  
SO PCT Int. Appl., 146pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009073153	A2	20090611	WO 2008-US13219	20081128
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2007-4462P P 20071128

OS MARPAT 151:49314

IT	778276-24-7P	778276-36-1P	1160701-89-2P
	1160701-92-7P	1160701-94-9P	1160703-31-0P
	1160703-32-1P	1160703-33-2P	1160703-34-3P
	1160703-35-4P	1160703-36-5P	1160703-37-6P
	1160703-38-7P	1160703-39-8P	1160703-40-1P
	1160703-41-2P	1160703-42-3P	1160703-43-4P
	1160703-44-5P	1160703-45-6P	1160703-46-7P
	1160703-47-8P	1160703-48-9P	1160703-49-0P
	1160703-50-3P	1160703-51-4P	1160703-52-5P
	1160703-53-6P	1160703-54-7P	1160703-55-8P
	1160703-56-9P	1160703-57-0P	1160703-58-1P
	1160703-59-2P	1160703-60-5P	1160703-61-6P
	1160703-64-9P	1160703-65-0P	1160703-67-2P
	1160703-69-4P	1160703-70-7P	1160703-71-8P
	1160703-72-9P	1160703-73-0P	1160703-74-1P
	1160703-75-2P	1160703-76-3P	1160703-77-4P
	1160703-78-5P	1160703-79-6P	1160703-80-9P
	1160703-81-0P	1160703-82-1P	1160703-83-2P
	1160703-84-3P	1160703-85-4P	1160703-86-5P
	1160703-87-6P	1160703-88-7P	1160703-89-8P
	1160703-90-1P	1160703-91-2P	1160703-92-3P
	1160703-93-4P	1160703-94-5P	1160703-95-6P
	1160703-96-7P	1160703-97-8P	


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(antitumor myristate inhibitors of bcr-abl)

RN 778276-24-7 CAPLUS


CN Benzenesulfonamide, 4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)

10/817,328




RN 778276-36-1 CAPLUS

CN 4-Pyrimidinamine, 6-[4-(4-morpholinylsulfonyl)phenyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 1160701-89-2 CAPLUS

CN Benzamide, 4-[5-methyl-6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 1160701-92-7 CAPLUS


CN 4-Pyrimidinamine, 6-(1H-pyrrolo[2,3-b]pyridin-1-yl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 1160701-94-9 CAPLUS


CN 4-Pyrimidinamine, N-[4-(trifluoromethoxy)phenyl]-6-(1,3,5-trimethyl-1H-pyrazol-4-yl)- (CA INDEX NAME)

10/817,328




RN 1160703-31-0 CAPLUS

CN Benzenesulfonamide, 4-[5-methyl-6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1160703-32-1 CAPLUS

CN Benzenesulfonamide, N-methyl-4-[5-methyl-6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 1160703-33-2 CAPLUS


CN Benzenesulfonamide, N-ethyl-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1160703-34-3 CAPLUS

CN Benzenesulfonamide, N-(2-hydroxyethyl)-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)


10/817,328




RN 1160703-35-4 CAPLUS  
CN 4-Pyrimidinamine, 6-[4-(methylsulfonyl)phenyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 1160703-36-5 CAPLUS  
CN 4-Pyrimidinamine, 5-methyl-6-[4-(methylsulfonyl)phenyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 1160703-37-6 CAPLUS  
CN 4-Pyrimidinamine, 6-[4-[(1-methylethyl)sulfonyl]phenyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 1160703-38-7 CAPLUS  
CN 4-Pyrimidinamine, 5-methyl-6-[4-[(1-methylethyl)sulfonyl]phenyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




10/817,328




RN 1160703-39-8 CAPLUS

CN Benzenesulfonamide, N,N-diethyl-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1160703-40-1 CAPLUS

CN Benzenesulfonamide, N,N-diethyl-4-[5-methyl-6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 1160703-41-2 CAPLUS


CN 4-Pyrimidinamine, 6-[4-(1-piperidinylsulfonyl)phenyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 1160703-42-3 CAPLUS


CN Benzenesulfonamide, 4-methyl-N-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)

10/817,328




RN 1160703-43-4 CAPLUS

CN Benzenesulfonamide, 4-methyl-N-[4-[5-methyl-6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 1160703-44-5 CAPLUS

CN Methanesulfonamide, N-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)



RN 1160703-45-6 CAPLUS


CN Ethanesulfonamide, N-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)



RN 1160703-46-7 CAPLUS


CN 1-Butanesulfonamide, N-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)

10/817,328




RN 1160703-47-8 CAPLUS

CN 2-Propanesulfonamide, N-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 1160703-48-9 CAPLUS

CN 2-Pentanesulfonamide, N-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)



RN 1160703-49-0 CAPLUS


CN Benzamide, N-(2-hydroxyethyl)-4-[5-methyl-6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 1160703-50-3 CAPLUS


CN Benzamide, N-(3-methoxypropyl)-4-[5-methyl-6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)

10/817,328




RN 1160703-51-4 CAPLUS

CN Acetamide, N-[3-[5-methyl-6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 1160703-52-5 CAPLUS

CN Benzamide, 3-[5-methyl-6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1160703-53-6 CAPLUS

CN Benzoic acid, 3-[5-methyl-6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 1160703-54-7 CAPLUS


CN 4-Pyrimidinamine, 6-[1,1'-biphenyl]-4-yl-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



10/817,328


RN 1160703-55-8 CAPLUS

CN 4-Pyrimidinamine, 6-[1,1'-biphenyl]-4-yl-5-methyl-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 1160703-56-9 CAPLUS

CN 4-Pyrimidinamine, 6-(8-methoxy-2-naphthalenyl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 1160703-57-0 CAPLUS

CN 4-Pyrimidinamine, 6-(8-methoxy-2-naphthalenyl)-5-methyl-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 1160703-58-1 CAPLUS


CN Benzeneacetonitrile, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 1160703-59-2 CAPLUS


CN 4-Pyrimidinamine, 6-(3-nitrophenyl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

10/817,328




RN 1160703-60-5 CAPLUS

CN Benzamide, 4-methoxy-N-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 1160703-61-6 CAPLUS

CN 4-Pyrimidinamine, 6-[4-(aminomethyl)phenyl]-5-methyl-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 1160703-64-9 CAPLUS


CN 4-Morpholineethanamine, N-[1-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-1H-imidazol-2-yl]- (CA INDEX NAME)



RN 1160703-65-0 CAPLUS


CN 4-Pyrimidinamine, N-[4-(trifluoromethoxy)phenyl]-6-[2-[[4-(trifluoromethoxy)phenyl]amino]-1H-imidazol-1-yl]- (CA INDEX NAME)

10/817,328




RN 1160703-67-2 CAPLUS

CN 4-Pyrimidinamine, 6-(3-amino-5-cyclopropyl-1H-pyrazol-1-yl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 1160703-69-4 CAPLUS


CN 4-Pyrimidinamine, 6-(1H-pyrazol-4-yl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 1160703-70-7 CAPLUS


CN 4-Pyrimidinamine, 6-(1-methyl-1H-pyrazol-4-yl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

10/817,328




RN 1160703-71-8 CAPLUS

CN 4-Pyrimidinamine, 6-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 1160703-72-9 CAPLUS

CN 4-Pyrimidinamine, 5-methyl-6-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 1160703-73-0 CAPLUS

CN 4-Pyrimidinamine, 6-[1-[[4-(methylsulfonyl)phenyl]methyl]-1H-pyrazol-4-yl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




10/817,328



RN 1160703-74-1 CAPLUS


CN 4-Pyrimidinamine, 6-[1-(ethylsulfonyl)-1H-pyrazol-4-yl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 1160703-75-2 CAPLUS


CN 4-Pyrimidinamine, 6-[1-(4-pyridinylmethyl)-1H-pyrazol-4-yl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

10/817,328




RN 1160703-76-3 CAPLUS

CN [4,4'-Bipyrimidine]-6,6'-diamine, N6-[2-(4-morpholinyl)ethyl]-N6'-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 1160703-77-4 CAPLUS


CN 4-Pyrimidinamine, 5-methyl-6-(1-methyl-1H-pyrazol-4-yl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 1160703-78-5 CAPLUS


CN 4-Pyrimidinamine, 6-(5-methyl-1-phenyl-1H-pyrazol-4-yl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

10/817,328




RN 1160703-79-6 CAPLUS

CN 4-Pyrimidinamine, 5-methyl-6-(5-methyl-1-phenyl-1H-pyrazol-4-yl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 1160703-80-9 CAPLUS

CN 4-Pyrimidinamine, 6-(1H-indol-7-yl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 1160703-81-0 CAPLUS

CN 4-Pyrimidinamine, 6-(1H-indol-3-yl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 1160703-82-1 CAPLUS

CN 4-Pyrimidinamine, 6-(1H-indol-6-yl)-N-[4-(trifluoromethoxy)phenyl]- (CA


10/817,328

INDEX NAME)




RN 1160703-83-2 CAPLUS

CN 2-Furancarboxaldehyde, 4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 1160703-84-3 CAPLUS

CN 4-Pyrimidinamine, 6-benzo[b]thien-7-yl-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 1160703-85-4 CAPLUS


CN 4-Pyrimidinamine, 6-(1H-indol-7-yl)-5-methyl-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 1160703-86-5 CAPLUS

CN 4-Pyrimidinamine, 6-(4-dibenzofuranyl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)


10/817,328




RN 1160703-87-6 CAPLUS  
CN 4-Pyrimidinamine, 6-[1-(phenylmethyl)-1H-pyrazol-4-yl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 1160703-88-7 CAPLUS  
CN 4-Pyrimidinamine, 5-methyl-6-[1-(phenylmethyl)-1H-pyrazol-4-yl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 1160703-89-8 CAPLUS  
CN [4,4'-Bipyrimidine]-6,6'-diamine, N6,N6'-bis[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 1160703-90-1 CAPLUS  
CN Benzamide, N-[4-methyl-3-[[1-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-1H-imidazol-2-yl]amino]phenyl]- (CA INDEX NAME)

10/817,328




RN 1160703-91-2 CAPLUS

CN Benzamide, N-[4-methyl-3-[[1-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-1H-imidazol-2-yl]amino]phenyl]-4-(4-morpholinylmethyl)-3-(trifluoromethyl)- (CA INDEX NAME)



RN 1160703-92-3 CAPLUS


CN 4-Pyrimidinamine, 6-[1-(3-pyridinylmethyl)-1H-pyrazol-4-yl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 1160703-93-4 CAPLUS


CN 4-Pyrimidinamine, 6-(1H-pyrrolo[2,3-b]pyridin-4-yl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

10/817,328




RN 1160703-94-5 CAPLUS

CN 2(1H)-Pyridinone, 4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-  
(CA INDEX NAME)




RN 1160703-95-6 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methyl-4-thiazolyl)-N-[4-(trifluoromethoxy)phenyl]-  
(CA INDEX NAME)




RN 1160703-96-7 CAPLUS

CN Benzaldehyde, 2-fluoro-5-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-  
(CA INDEX NAME)




RN 1160703-97-8 CAPLUS

CN 4-Pyrimidinamine, 6-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-N-[4-(trifluoromethoxy)phenyl]-  
(CA INDEX NAME)




10/817,328

IT 1160701-90-5P 1160701-91-6P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(antitumor myristate inhibitors of bcr-abl)  
RN 1160701-90-5 CAPLUS  
CN 4-Pyrimidinamine, 6-(4-chlorophenyl)-5-methyl-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 1160701-91-6 CAPLUS  
CN Benzoic acid, 4-[5-methyl-6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)






10/817,328

L4 ANSWER 3 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 2009:237899 CAPLUS  
DN 150:252611  
TI Methods and compositions of a hedgehog signaling antagonist and a BCR-ABL  
inhibitor for treating cancers  
IN Dierks, Christine; Warmuth, Markus  
PA Irm LLC, Bermuda  
SO PCT Int. Appl., 49pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009026075	A1	20090226	WO 2008-US73049	20080813
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2007-956295P	P	20070816		
IT	778270-11-4, GNF 2				
	RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combination of hedgehog signaling antagonist and BCR-ABL inhibitor for treating cancers)				
RN	778270-11-4 CAPLUS				
CN	Benzamide, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)				



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/817,328


L4 ANSWER 4 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 2009:80325 CAPLUS  
DN 150:321331  
TI An intracellular conformational sensor assay for Abl T315I  
AU Zhou, Vicki; Gao, Xiaoqi; Han, Shulin; Brinker, Achim; Caldwell, Jeremy  
S.; Gu, Xiang-Ju  
CS Genomics Institute of the Novartis Research Foundation, San Diego, CA,  
92121, USA  
SO Analytical Biochemistry (2009), 385(2), 300-308  
CODEN: ANBCA2; ISSN: 0003-2697  
PB Elsevier B.V.  
DT Journal  
LA English  
IT 778270-11-4  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(intracellular conformational sensor assay for Abl T315I)  
RN 778270-11-4 CAPLUS  
CN Benzamide, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA  
INDEX NAME)



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/817,328

L4 ANSWER 5 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 2009:5955 CAPLUS  
DN 150:274884  
TI Identification of a small molecule  $\beta$ -secretase inhibitor that binds  
without catalytic aspartate engagement  
AU Steele, Thomas G.; Hills, Ivory D.; Nomland, Ashley A.; de Leon, Pablo;  
Allison, Timothy; McGaughey, Georgia; Colussi, Dennis; Tugusheva,  
Katherine; Haugabook, Sharie J.; Espeseth, Amy S.; Zuck, Paul; Graham,  
Samuel L.; Stachel, Shawn J.  
CS Department of Medicinal Chemistry, Merck Research Laboratories, Merck and  
Co., West Point, PA, 19486, USA  
SO Bioorganic & Medicinal Chemistry Letters (2009), 19(1), 17-20  
CODEN: BMCLE8; ISSN: 0960-894X  
PB Elsevier Ltd.  
DT Journal  
LA English  
IT 1123311-31-8  
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
(small mol.  $\beta$ -secretase inhibitor binding without catalytic  
aspartate engagement)  
RN 1123311-31-8 CAPLUS  
CN 1,3-Benzenediamine, 4-bromo-N1-(6-phenyl-4-pyrimidinyl)- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)  
RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2008:640658 CAPLUS

DN 149:9754

TI Preparation of 2-hydroxy-1,3-diaminopropane derivatives for the treatment of neurological or vascular disorders

IN Frederiksen, Mathias; Lueoend, Rainer Martin; McCarthy, Clive; Moebitz, Henrik; Rondeau, Jean-Michel; Roy, Bernard Lucien; Rueeger, Heinrich

PA Novartis A.-G., Switz.

SO PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008062044	A1	20080529	WO 2007-EP62701	20071122
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2007324490	A1	20080529	AU 2007-324490	20071122
	CA 2669839	A1	20080529	CA 2007-2669839	20071122
	KR 2009091139	A	20090826	KR 2009-710477	20071122
	EP 2094645	A1	20090902	EP 2007-847275	20071122
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR				
	CN 101528670	A	20090909	CN 2007-80040090	20090427
	MX 2009005182	A	20090525	MX 2009-5182	20090514
PRAI	EP 2006-124689	A	20061123		
	WO 2007-EP62701	W	20071122		

OS MARPAT 149:9754

IT 1029718-95-3P, (2S,3S)-3-Amino-1-chloro-4-[4-[(6-phenylpyrimidin-4-yl)amino]phenyl]butan-2-ol 1029718-96-4P,

N-[(1S,2S)-3-Chloro-2-hydroxy-1-[4-[(6-phenylpyrimidin-4-yl)amino]benzyl]propyl]acetamide

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of hydroxydiaminopropane derivs. for the treatment of neurol. or vascular disorders)

RN 1029718-95-3 CAPLUS

CN Benzenepropanol,  $\beta$ -amino- $\alpha$ -(chloromethyl)-4-[(6-phenyl-4-pyrimidinyl)amino]-, ( $\alpha$ S, $\beta$ S)- (CA INDEX NAME)

Absolute stereochemistry.


10/817,328



RN 1029718-96-4 CAPLUS

CN Acetamide, N-[(1S,2S)-3-chloro-2-hydroxy-1-[[4-[(6-phenyl-4-pyrimidinyl)amino]phenyl]methyl]propyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/817,328

L4 ANSWER 7 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 2006:1249826 CAPLUS  
DN 146:781  
TI Methods of treating pain  
IN Wabnitz, Philipp; Schauerte, Heike; Stumm, Gabriele; Freitag, Joachim  
PA Ingenium Pharmaceuticals A.-G., Germany  
SO PCT Int. Appl., 132pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2006125616	A2	20061130	WO 2006-EP4924	20060524
	WO 2006125616	A3	20070419		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	EP 1901747	A2	20080326	EP 2006-743044	20060524
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
	JP 2008542219	T	20081127	JP 2008-512757	20060524
	US 20090221581	A1	20090903	US 2009-920883	20090118
PRAI	US 2005-684345P	P	20050525		
	WO 2006-EP4924	W	20060524		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OS MARPAT 146:781

IT 848636-35-1 848637-36-5 848637-37-6  
848637-64-9 848638-16-4 848638-17-5  
848638-99-3 848639-00-9 848639-90-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(methods of treating pain)

RN 848636-35-1 CAPLUS


CN 1,4-Benzenediamine, N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 848637-36-5 CAPLUS


CN 1,4-Benzenediamine, N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]-2-methyl- (CA INDEX NAME)

10/817,328




RN 848637-37-6 CAPLUS

CN 1,3-Benzenediamine, N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 848637-64-9 CAPLUS

CN 1,4-Benzenediamine, N1-[6-(2-methoxyphenyl)-5-methyl-4-pyrimidinyl]- (CA INDEX NAME)




RN 848638-16-4 CAPLUS

CN 1,4-Benzenediamine, N1-[6-(2-methoxyphenyl)-2-methyl-4-pyrimidinyl]- (CA INDEX NAME)



RN 848638-17-5 CAPLUS


CN 1,4-Benzenediamine, N1-[6-(4-methoxyphenyl)-2-methyl-4-pyrimidinyl]- (CA INDEX NAME)



10/817,328


RN 848638-99-3 CAPLUS

CN 1,4-Benzenediamine, N1-[6-(4-methoxyphenyl)-5-methyl-4-pyrimidinyl]- (CA  
INDEX NAME)




RN 848639-00-9 CAPLUS

CN 1,4-Benzenediamine, N1-[6-(3-aminophenyl)-5-methyl-4-pyrimidinyl]- (CA  
INDEX NAME)



RN 848639-90-7 CAPLUS

CN 1,3-Benzenediamine, 4-chloro-N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (CA  
INDEX NAME)



OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT



10/817,328

L4 ANSWER 8 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 2006:388497 CAPLUS  
DN 144:432833  
TI Preparation of substituted nitrogen-containing heterocycles as vanilloid  
receptor ligands for treating various diseases  
IN Norman, Mark H.; Ognyanov, Vassil I.; Rzasa, Robert M.  
PA Amgen Inc., USA  
SO U.S. Pat. Appl. Publ., 34 pp.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060089360	A1	20060427	US 2005-256427	20051021
	US 7314933	B2	20080101		
	AU 2005299489	A1	20060504	AU 2005-299489	20051021
	CA 2584167	A1	20060504	CA 2005-2584167	20051021
	WO 2006047492	A2	20060504	WO 2005-US38327	20051021
	WO 2006047492	A3	20070419		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	EP 1807418	A2	20070718	EP 2005-817010	20051021
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
PRAI	US 2004-621139P	P	20041022		
	WO 2005-US38327	W	20051021		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 144:432833

IT 851984-86-6P 851984-90-2P 851985-04-1P  
851985-06-3P 852063-00-4P 885111-17-1P  
885111-18-2P 885111-19-3P 885111-20-6P  
885111-21-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of substituted nitrogen-containing heterocycles as vanilloid  
receptor ligands for treating various diseases)


RN 851984-86-6 CAPLUS

CN 4-Pyrimidinamine, 6-(8-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA  
INDEX NAME)


10/817,328




RN 851984-90-2 CAPLUS  
CN 4-Pyrimidinamine, 6-(7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA  
INDEX NAME)



RN 851985-04-1 CAPLUS  
CN 4-Pyrimidinamine, 6-(5-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA  
INDEX NAME)




RN 851985-06-3 CAPLUS  
CN 4-Pyrimidinamine, 6-(6-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA  
INDEX NAME)




RN 852063-00-4 CAPLUS  
CN 4-Pyrimidinamine, 6-(6-quinoxal-2-yl)-N-[4-(trifluoromethyl)phenyl]- (CA  
INDEX NAME)

10/817,328




RN 885111-17-1 CAPLUS

CN 4-Pyrimidinamine, 6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 885111-18-2 CAPLUS

CN 4-Pyrimidinamine, 6-(1H-indol-5-yl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 885111-19-3 CAPLUS

CN 4-Pyrimidinamine, 6-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 885111-20-6 CAPLUS


CN 4-Pyrimidinamine, 6-(2,3-dihydro-5-benzofuranyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 885111-21-7 CAPLUS

10/817,328

CN 4-Pyrimidinamine, 6-(5-isoquinoliny1)-N-[4-(trifluoromethyl)phenyl]- (CA  
INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/817,328

L4 ANSWER 9 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 2006:343626 CAPLUS  
DN 144:382034  
TI Besylate salts of six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain and other conditions requiring administration of a VR1 antagonist  
IN Cai, Dongwei; Jones, A. Brian  
PA Merck Sharp & Dohme Limited, UK; Merck & Co., Inc.  
SO PCT Int. Appl., 27 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006038041	A1	20060413	WO 2005-GB50172	20051004
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2004-617134P	P	20041008		
OS	MARPAT 144:382034				
IT	882686-43-3P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(besylate salts of six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain and other conditions requiring administration of VR1 antagonist)				
RN	882686-43-3 CAPLUS				
CN	4-Pyrimidinamine, 6-(6-fluoro-7-quinolinyl)-5-methyl-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)				

CM 1

CRN 851985-53-0  
CMF C21 H14 F4 N4




10/817,328

CM 2

CRN 98-11-3

CMF C6 H6 O3 S



IT	882685-36-1	882685-39-4	882685-44-1
	882685-46-3	882685-48-5	882685-50-9
	882685-51-0	882685-52-1	882685-53-2
	882685-54-3	882685-55-4	882685-56-5
	882685-57-6	882685-59-8	882685-70-3
	882685-72-5	882685-74-7	882685-80-5
	882685-81-6	882685-83-8	882685-84-9
	882685-90-7	882685-96-3	882686-00-2
	882686-02-4	882686-31-9	882686-32-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(besylate salts of six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain and other conditions requiring administration of VR1 antagonist)


RN 882685-36-1 CAPLUS

CN 4-Pyrimidinamine, 6-(8-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 851984-86-6

CMF C20 H13 F3 N4




CM 2

CRN 98-11-3

CMF C6 H6 O3 S


10/817,328



RN 882685-39-4 CAPLUS  
CN 4-Pyrimidinamine, 6-(7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 851984-90-2  
CMF C20 H13 F3 N4



CM 2


CRN 98-11-3  
CMF C6 H6 O3 S



RN 882685-44-1 CAPLUS  
CN 4-Pyrimidinamine, 6-(5-methoxy-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 882685-43-0  
CMF C21 H15 F3 N4 O




10/817,328

CM 2

CRN 98-11-3

CMF C6 H6 O3 S




RN 882685-46-3 CAPLUS

CN 4-Pyrimidinamine, 6-(5-methyl-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 882685-45-2


CMF C21 H15 F3 N4



CM 2

CRN 98-11-3

CMF C6 H6 O3 S



RN 882685-48-5 CAPLUS

CN 4-Pyrimidinamine, 6-(5-fluoro-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 882685-47-4

CMF C20 H12 F4 N4




10/817,328



CM 2

CRN 98-11-3

CMF C6 H6 O3 S




RN 882685-50-9 CAPLUS

CN 4-Pyrimidinamine, 2-methyl-6-(7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 851985-02-9


CMF C21 H15 F3 N4



CM 2

CRN 98-11-3

CMF C6 H6 O3 S



10/817,328


RN 882685-51-0 CAPLUS

CN 4-Pyrimidinamine, 6-(3-methyl-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 851985-03-0


CMF C21 H15 F3 N4



CM 2

CRN 98-11-3

CMF C6 H6 O3 S




RN 882685-52-1 CAPLUS

CN 4-Pyrimidinamine, 6-(5-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 851985-04-1

CMF C20 H13 F3 N4




CM 2

CRN 98-11-3

CMF C6 H6 O3 S

10/817,328




RN 882685-53-2 CAPLUS

CN 4-Pyrimidinamine, 6-(6-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 851985-06-3


CMF C20 H13 F3 N4



CM 2

CRN 98-11-3

CMF C6 H6 O3 S




RN 882685-54-3 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methyl-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 851985-07-4


CMF C21 H15 F3 N4



CM 2

10/817,328


CRN 98-11-3  
CMF C6 H6 O3 S



RN 882685-55-4 CAPLUS  
CN 4-Pyrimidinamine, 6-(6-fluoro-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-  
, benzenesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 851985-08-5  
CMF C20 H12 F4 N4



CM 2

CRN 98-11-3  
CMF C6 H6 O3 S




RN 882685-56-5 CAPLUS  
CN 4-Pyrimidinamine, 6-(8-fluoro-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-  
, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 851985-10-9  
CMF C20 H12 F4 N4


10/817,328



CM 2

CRN 98-11-3

CMF C6 H6 O3 S




RN 882685-57-6 CAPLUS

CN 4-Pyrimidinamine, 6-(8-methyl-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 851985-14-3


CMF C21 H15 F3 N4



CM 2

CRN 98-11-3

CMF C6 H6 O3 S




RN 882685-59-8 CAPLUS

CN 4-Pyrimidinamine, 6-(7-isoquinolinyl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

10/817,328


CM 1

CRN 851985-18-7  
CMF C20 H13 F3 N4



CM 2


CRN 98-11-3  
CMF C6 H6 O3 S



RN 882685-70-3 CAPLUS  
CN 4-Pyrimidinamine, 6-(8-ethyl-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 852062-40-9  
CMF C22 H17 F3 N4



CM 2

CRN 98-11-3  
CMF C6 H6 O3 S



10/817,328


RN 882685-72-5 CAPLUS

CN 4-Pyrimidinamine, 6-(8-ethyl-7-quinolinyl)-5-methyl-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 852062-42-1


CMF C23 H19 F3 N4



CM 2

CRN 98-11-3

CMF C6 H6 O3 S




RN 882685-74-7 CAPLUS

CN 4-Pyrimidinamine, N-[2-fluoro-4-(trifluoromethyl)phenyl]-5-methyl-6-(7-quinolinyl)-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 852062-44-3

CMF C21 H14 F4 N4




CM 2

CRN 98-11-3

CMF C6 H6 O3 S

10/817,328




RN 882685-80-5 CAPLUS

CN 4-Pyrimidinamine, 6-(1,8-naphthyridin-2-yl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 852062-51-2


CMF C19 H12 F3 N5



CM 2

CRN 98-11-3

CMF C6 H6 O3 S




RN 882685-81-6 CAPLUS

CN 4-Pyrimidinamine, 5-methyl-6-(8-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 852062-52-3

CMF C21 H15 F3 N4






10/817,328

CM 2

CRN 98-11-3

CMF C6 H6 O3 S




RN 882685-83-8 CAPLUS

CN 4-Pyrimidinamine, N-[4-(trifluoromethyl)phenyl]-6-[4-(trifluoromethyl)-7-quinolinyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 852062-54-5


CMF C21 H12 F6 N4



CM 2

CRN 98-11-3

CMF C6 H6 O3 S



RN 882685-84-9 CAPLUS


CN 4-Pyrimidinamine, 5-methyl-N-[4-(trifluoromethyl)phenyl]-6-[4-(trifluoromethyl)-7-quinolinyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 852062-55-6

CMF C22 H14 F6 N4


10/817,328



CM 2

CRN 98-11-3

CMF C6 H6 O3 S




RN 882685-90-7 CAPLUS

CN 4-Pyrimidinamine, 5-methyl-6-(1,8-naphthyridin-2-yl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 852062-61-4


CMF C20 H14 F3 N5



CM 2

CRN 98-11-3

CMF C6 H6 O3 S



RN 882685-96-3 CAPLUS


10/817,328

CN 4-Pyrimidinamine, 5-methyl-6-(1,5-naphthyridin-3-yl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 852062-66-9


CMF C20 H14 F3 N5



CM 2

CRN 98-11-3

CMF C6 H6 O3 S




RN 882686-00-2 CAPLUS

CN 4-Pyrimidinamine, 5-methyl-6-(1-methyl-1H-benzimidazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 852062-68-1

CMF C20 H16 F3 N5




CM 2

CRN 98-11-3

CMF C6 H6 O3 S


10/817,328



RN 882686-02-4 CAPLUS  
CN 4-Pyrimidinamine, 6-(1H-benzimidazol-6-yl)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 852062-69-2  
CMF C18 H12 F3 N5



CM 2


CRN 98-11-3  
CMF C6 H6 O3 S



RN 882686-31-9 CAPLUS  
CN 4-Pyrimidinamine, 6-(6-quinoxaliny)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 852063-00-4  
CMF C19 H12 F3 N5



10/817,328

CM 2


CRN 98-11-3  
CMF C6 H6 O3 S



RN 882686-32-0 CAPLUS  
CN 4-Pyrimidinamine, 5-methyl-6-(6-quinoxaliny)-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 852063-01-5  
CMF C20 H14 F3 N5




CM 2

CRN 98-11-3  
CMF C6 H6 O3 S



IT 851985-53-0  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(besylate salts of six-membered amino-heterocycles as vanilloid-1  
receptor antagonists for treating pain and other conditions requiring  
administration of VR1 antagonist)  
RN 851985-53-0 CAPLUS  
CN 4-Pyrimidinamine, 6-(6-fluoro-7-quinolinyl)-5-methyl-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)

10/817,328



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/817,328

L4 ANSWER 10 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 2006:301346 CAPLUS  
DN 144:350708  
TI Novel pyrimidine compounds, process for their preparation, pharmaceutical compositions, and their use as antiinflammatory, cytotoxic, rheumatic, immunosuppressive and cardiovascular agents for treatment of diseases  
IN Kalleda, Srinivas; Padakanti, Srinivas; Kumar Swamy, Nalivela; Yeleswarapu, Koteswar Rao; Alexander, Christopher W.; Khanna, Ish Kumar; Iqbal, Javed; Pillarisetti, Sivaram; Pal, Manojit; Barange, Deepak  
PA Reddy US Therapeutics, Inc., USA  
SO PCT Int. Appl., 336 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2006034473	A2	20060330	WO 2005-US34243	20050923
	WO 2006034473	A3	20061214		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	AU 2005286592	A1	20060330	AU 2005-286592	20050923
	CA 2581454	A1	20060330	CA 2005-2581454	20050923
	US 20060084644	A1	20060420	US 2005-234257	20050923
	US 7622486	B2	20091124		
	US 20060084645	A1	20060420	US 2005-234695	20050923
	EP 1796673	A2	20070620	EP 2005-799686	20050923
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
	JP 2008538544	T	20081030	JP 2007-533673	20050923
	IN 2007CN01626	A	20070831	IN 2007-CN1626	20070420
	ZA 2007003277	A	20080625	ZA 2007-3277	20070420
PRAI	US 2004-612374P	P	20040923		
	WO 2005-US34243	W	20050923		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 144:350708

IT 881194-14-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidine compds. and their use as antiinflammatory, proliferative, rheumatic, immunosuppressive and cardiovascular agents for treatment of diseases)

RN 881194-14-5 CAPLUS

CN 4-Pyrimidinamine, 6-phenyl-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

10/817,328




OSC.G	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT	1	THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT




10/817,328

L4 ANSWER 11 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 2006:49982 CAPLUS  
DN 144:205343  
TI Allosteric inhibitors of Bcr-abl-dependent cell proliferation  
AU Adrian, Francisco J.; Ding, Qiang; Sim, Taebo; Velentza, Anastasia; Sloan, Christine; Liu, Yi; Zhang, Guobao; Hur, Wooyoung; Ding, Sheng; Manley, Paul; Mestan, Juergen; Fabbro, Dorian; Gray, Nathanael S.  
CS Biological Chemistry Department, Genomics Institute of the Novartis Research Foundation, San Diego, CA, 92121, USA  
SO Nature Chemical Biology (2006), 2(2), 95-102  
CODEN: NCBABT; ISSN: 1552-4450  
PB Nature Publishing Group  
DT Journal  
LA English  
IT 778270-11-4, GNF 2 875557-38-3, GNF 3  
875557-39-4, GNF 4  
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(allosteric inhibitors of Bcr-abl-dependent cell proliferation)  
RN 778270-11-4 CAPLUS  
CN Benzamide, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 875557-38-3 CAPLUS  
CN Benzamide, N-(17-amino-3,6,9,12,15-pentaoxaheptadec-1-yl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 875557-39-4 CAPLUS  
CN Benzamide, N-(17-amino-3,6,9,12,15-pentaoxaheptadec-1-yl)-3-[6-[methyl[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)

10/817,328

PAGE 1-A



PAGE 1-B



OSC.G	45	THERE ARE 45 CAPLUS RECORDS THAT CITE THIS RECORD (45 CITINGS)
RE.CNT	35	THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/817,328

L4 ANSWER 12 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2006:10841 CAPLUS

DN 144:108340

TI Preparation of 4,6-disubstituted pyrimidines and their use as kinase inhibitors, particularly protein kinase B/Akt inhibitors, for treating neoplasm

IN Wirschun, Wolfgang; Herdemann, Matthias; Stadlwieser, Josef; Baer, Thomas; Maier, Thomas; Beckers, Thomas; Ciossek, Thomas; Zuelch, Armin; Graedler, Ulrich

PA Altana Pharma AG, Germany

SO PCT Int. Appl., 92 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2006000589	A1	20060105	WO 2005-EP53019	20050628
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2005256659	A1	20060105	AU 2005-256659	20050628
	CA 2570552	A1	20060105	CA 2005-2570552	20050628
	EP 1763526	A1	20070321	EP 2005-769611	20050628
	EP 1763526	B1	20090624		
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
	CN 1972934	A	20070530	CN 2005-80020545	20050628
	JP 2008504251	T	20080214	JP 2007-517306	20050628
	BR 2005012547	A	20080325	BR 2005-12547	20050628
	AT 434614	T	20090715	AT 2005-769611	20050628
	ZA 2006009637	A	20080827	ZA 2006-9637	20061120
	MX 2006014747	A	20070216	MX 2006-14747	20061215
	US 20070208034	A1	20070906	US 2006-630352	20061221
	IN 2007MN00076	A	20080215	IN 2007-MN76	20070117
	KR 2007027723	A	20070309	KR 2007-701451	20070119
PRAI	EP 2004-103011	A	20040628		
	EP 2005-102355	A	20050323		
	WO 2005-EP53019	W	20050628		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 144:108340; MARPAT 144:108340

IT 872601-51-9P, N-[6-(Dibenzofuran-4-yl)pyrimidin-4-yl]benzene-1,4-diamine trifluoroacetate 872601-94-0P,  
N-[6-(Dibenzofuran-4-yl)pyrimidin-4-yl]benzene-1,3-diamine trifluoroacetate 872602-59-0P,  
N'-[6-(Dibenzofuran-4-yl)pyrimidin-4-yl]-4-methylbenzene-1,3-diamine  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(intermediate; preparation of disubstituted pyrimidines and their use as protein kinase B/Akt inhibitors for treating hyperproliferative

10/817,328

diseases and/or disorders responsive to the induction of apoptosis)


RN 872601-51-9 CAPLUS

CN 1,4-Benzenediamine, N1-[6-(4-dibenzofuranyl)-4-pyrimidinyl]-,  
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 872601-50-8


CMF C22 H16 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 872601-94-0 CAPLUS

CN 1,3-Benzenediamine, N1-[6-(4-dibenzofuranyl)-4-pyrimidinyl]-,  
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 872601-93-9

CMF C22 H16 N4 O




CM 2

CRN 76-05-1


CMF C2 H F3 O2

10/817,328



RN 872602-59-0 CAPLUS

CN 1,3-Benzenediamine, N3-[6-(4-dibenzofuranyl)-4-pyrimidinyl]-4-methyl- (CA  
INDEX NAME)




RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/817,328

L4 ANSWER 13 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 2005:696886 CAPLUS  
DN 143:194017  
TI Preparation of heteroaryl-substituted  
pyrimidinylaminophenylbezene-sulfonamides as kinase inhibitors  
IN Barsig, Johannes; Baudler, Monika; Bundschuh, Daniela; Gantner, Florian;  
Graedler, Ulrich; Heit, Isabelle; Martin, Thomas; Schaefer, Michaela;  
Schlemminger, Imre; Stadlwieser, Josef; Ulrich, Wolf-Ruediger  
PA Altana Pharma A.-G., Germany  
SO PCT Int. Appl., 115 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005070900	A1	20050804	WO 2005-EP50206	20050119
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2553513	A1	20050804	CA 2005-2553513	20050119
	EP 1709007	A1	20061011	EP 2005-701549	20050119
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	US 20080242681	A1	20081002	US 2006-586121	20060825
PRAI	EP 2004-1310	A	20040122		
	WO 2005-EP50206	W	20050119		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
OS CASREACT 143:194017; MARPAT 143:194017  
IT 861846-69-7P, N-[6-(4-Fluorophenyl)pyrimidin-4-yl]benzene-1,4-diamine 861851-03-8P, N-[6-(2-Methyl-2,3-dihydrobenzofuran-5-yl)pyrimidin-4-yl]benzene-1,4-diamine dihydrochloride  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of heteroaryl-substituted  
pyrimidinylaminophenylbezene-sulfonamides as kinase inhibitors)  
RN 861846-69-7 CAPLUS  
CN 1,4-Benzenediamine, N1-[6-(4-fluorophenyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 861851-03-8 CAPLUS  
CN 1,4-Benzenediamine, N1-[6-(2,3-dihydro-2-methyl-5-benzofuranyl)-4-pyrimidinyl]-, hydrochloride (1:2) (CA INDEX NAME)

10/817,328



●2 HCl

OSC.G	2	THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT	3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/817,328

L4 ANSWER 14 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 2005:612254 CAPLUS  
DN 143:133396  
TI Preparation of heterocyclyl moiety-containing amides as BCR-ABL tyrosine  
kinase inhibitors  
IN Asaki, Tetsuo; Sugiyama, Yukiteru; Segawa, Jun  
PA Nippon Shinyaku Co., Ltd., Japan  
SO PCT Int. Appl., 168 pp.  
CODEN: PIXXD2  
DT Patent  
LA Japanese  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005063709	A1	20050714	WO 2004-JP19553	20041227
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004309248	A1	20050714	AU 2004-309248	20041227
	AU 2004309248	B2	20091105		
	CA 2551529	A1	20050714	CA 2004-2551529	20041227
	EP 1702917	A1	20060920	EP 2004-807908	20041227
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	CN 1898208	A	20070117	CN 2004-80039048	20041227
	BR 2004018074	A	20070417	BR 2004-18074	20041227
	CN 101456841	A	20090617	CN 2008-10186347	20041227
	MX 2006007237	A	20060818	MX 2006-7237	20060622
	IN 2006CN02337	A	20070706	IN 2006-CN2337	20060626
	KR 2006127901	A	20061213	KR 2006-714770	20060721
	KR 848067	B1	20080723		
	US 20080293940	A1	20081127	US 2008-584829	20080710
	IN 2009CN02791	A	20090821	IN 2009-CN2791	20090519
PRAI	JP 2003-431398	A	20031225		
	CN 2004-80039048	A3	20041227		
	WO 2004-JP19553	W	20041227		
	IN 2006-CN2337	A3	20060626		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 143:133396

IT 859213-24-4P, 4-Methyl-3-[6-(3-pyridyl)pyrimidin-4-ylamino]aniline 859213-26-6P,

4-Methyl-3-[6-(5-pyrimidinyl)pyrimidin-4-ylamino]aniline

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of heterocyclyl moiety-containing amides as BCR-ABL tyrosine kinase inhibitors)

RN 859213-24-4 CAPLUS

CN 1,3-Benzenediamine, 4-methyl-N3-[6-(3-pyridinyl)-4-pyrimidinyl]- (CA INDEX NAME)




10/817,328



RN 859213-26-6 CAPLUS

CN 1,3-Benzenediamine, N3-[4,5'-bipyrimidin]-6-yl-4-methyl- (CA INDEX NAME)




OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)  
RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/817,328

L4 ANSWER 15 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 2005:451377 CAPLUS  
DN 142:482070  
TI Preparation of (iso)quinolinyl pyridinamines, pyrimidinamines,  
pyrazinamines, pyridazinamines, and triazinamines as vanilloid-1 receptor  
antagonists for treating pain.  
IN Cai, Dongwei; Hollingworth, Gregory John; Jones, A. Brian; McIver, Edward  
Giles; Moyes, Christopher Richard; Rogers, Lauren  
PA Merck Sharp & Dohme Limited, UK; Merck & Co. Inc.  
SO PCT Int. Appl., 33 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 3


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2005047280	A1	20050526	WO 2004-GB4730	20041109
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20050197342	A1	20050908	US 2004-984336	20041109
PRAI	GB 2003-26217	A	20031110		
	GB 2004-7748	A	20040405		
	US 2004-617134P	P	20041008		
OS	CASREACT 142:482070; MARPAT 142:482070				
IT	851984-86-6P	851984-90-2P	851984-98-0P		
	851985-02-9P	851985-03-0P	851985-04-1P		
	851985-06-3P	851985-07-4P	851985-08-5P		
	851985-10-9P	851985-12-1P	851985-14-3P		
	851985-18-7P	851985-30-3P	851985-33-6P		
	851985-36-9P	851985-53-0P	851985-75-6P		
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (claimed compound; preparation of (iso)quinolinyl pyridinamines, pyrimidinamines, pyrazinamines, pyridazinamines, and triazinamines as vanilloid-1 receptor antagonists for treating pain)				
RN	851984-86-6 CAPLUS				
CN	4-Pyrimidinamine, 6-(8-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)				



10/817,328


RN 851984-90-2 CAPLUS

CN 4-Pyrimidinamine, 6-(7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 851984-98-0 CAPLUS

CN 4-Pyrimidinamine, 5-methyl-6-(7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 851985-02-9 CAPLUS

CN 4-Pyrimidinamine, 2-methyl-6-(7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851985-03-0 CAPLUS


CN 4-Pyrimidinamine, 6-(3-methyl-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851985-04-1 CAPLUS


CN 4-Pyrimidinamine, 6-(5-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)

10/817,328




RN 851985-06-3 CAPLUS

CN 4-Pyrimidinamine, 6-(6-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 851985-07-4 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methyl-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 851985-08-5 CAPLUS

CN 4-Pyrimidinamine, 6-(6-fluoro-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851985-10-9 CAPLUS


CN 4-Pyrimidinamine, 6-(8-fluoro-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



10/817,328


RN 851985-12-1 CAPLUS

CN 4-Pyrimidinamine, N-[4-(trifluoromethyl)phenyl]-6-[6-(trifluoromethyl)-7-quinolinyl]- (CA INDEX NAME)




RN 851985-14-3 CAPLUS

CN 4-Pyrimidinamine, 6-(8-methyl-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 851985-18-7 CAPLUS

CN 4-Pyrimidinamine, 6-(7-isoquinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851985-30-3 CAPLUS


CN 4-Pyrimidinamine, 6-(8-fluoro-7-quinolinyl)-5-methyl-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851985-33-6 CAPLUS


CN 4-Pyrimidinamine, 2-methyl-6-(8-methyl-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)

10/817,328




RN 851985-36-9 CAPLUS

CN 4-Pyrimidinamine, 5-methyl-6-(8-methyl-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851985-53-0 CAPLUS

CN 4-Pyrimidinamine, 6-(6-fluoro-7-quinolinyl)-5-methyl-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851985-75-6 CAPLUS


CN 4-Pyrimidinamine, 6-(6-fluoro-7-quinolinyl)-5-methyl-N-[4-(trifluoromethyl)phenyl]-, benzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 851985-53-0

CMF C21 H14 F4 N4


10/817,328



CM 2

CRN 98-11-3

CMF C6 H6 O3 S



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)  
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2005:451376 CAPLUS  
 DN 142:482069  
 TI Preparation of quinoxazolines and related derivatives vanilloid-1 receptor  
 antagonists for treating pain  
 IN Hollingworth, Gregory John; Jones, Brian A.; McIver, Edward Giles; Moyes,  
 Christopher Richard; Rogers, Lauren  
 PA Merck Sharp & Dohme Limited, UK  
 SO PCT Int. Appl., 108 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005047279	A1	20050526	WO 2004-GB4719	20041109
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004289518	A1	20050526	AU 2004-289518	20041109
	CA 2545384	A1	20050526	CA 2004-2545384	20041109
	US 20050197342	A1	20050908	US 2004-984336	20041109
	EP 1685124	A1	20060802	EP 2004-798442	20041109
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	JP 2007510706	T	20070426	JP 2006-538935	20041109
	CN 101035780	A	20070912	CN 2004-80039870	20041109
	IN 2006DN02615	A	20070824	IN 2006-DN2615	20060510
PRAI	GB 2003-26217	A	20031110		
	GB 2004-7748	A	20040405		
	US 2004-617134P	P	20041008		
	WO 2004-GB4719	W	20041109		
OS	CASREACT 142:482069; MARPAT 142:482069				
IT	851984-86-6P, 6-(Quinolin-8-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine			851984-90-2P, 6-(Quinolin-7-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine	
	851984-98-0P, 5-Methyl-6-(quinolin-7-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine			851985-02-9P, 2-Methyl-6-(quinolin-7-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine	
	851985-03-0P, 6-(3-Methylquinolin-7-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine			851985-04-1P, 6-(Quinolin-5-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine	
	851985-06-3P, 6-(Quinolin-6-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine			851985-07-4P, 6-(2-Methylquinolin-7-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine	
	851985-08-5P, 6-(6-Fluoroquinolin-7-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine			851985-10-9P, 6-(8-Fluoroquinolin-7-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine	
	851985-12-1P, N-[4-(Trifluoromethyl)phenyl]-6-[6-(trifluoromethyl)quinolin-7-yl]pyrimidin-4-amine			851985-14-3P, 6-(8-Methylquinolin-7-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine	
	851985-18-7P, 6-(Isoquinolin-7-yl)-N-(4-				




trifluoromethylphenyl)pyrimidin-4-amine 851985-30-3P,  
 6-(8-Fluoroquinolin-7-yl)-5-methyl-N-(4-trifluoromethylphenyl)pyrimidin-4-  
 amine 851985-33-6P, 2-Methyl-6-(8-methylquinolin-7-yl)-N-(4-  
 trifluoromethylphenyl)pyrimidin-4-amine 851985-36-9P,  
 5-Methyl-6-(8-methylquinolin-7-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-  
 amine 851985-53-0P, 6-(6-Fluoroquinolin-7-yl)-5-methyl-N-(4-  
 trifluoromethylphenyl)pyrimidin-4-amine 852062-40-9P,  
 6-(8-Ethylquinolin-7-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine  
 852062-42-1P, 6-(8-Ethylquinolin-7-yl)-5-methyl-N-(4-  
 trifluoromethylphenyl)pyrimidin-4-amine 852062-44-3P,  
 N-(2-Fluoro-4-trifluoromethylphenyl)-5-methyl-6-(quinolin-7-yl)pyrimidin-4-  
 amine 852062-51-2P 852062-52-3P,  
 5-Methyl-6-(quinolin-8-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine  
 852062-54-5P, N-(4-(Trifluoromethyl)phenyl)-6-(4-  
 (trifluoromethyl)quinolin-7-yl)pyrimidin-4-amine 852062-55-6P,  
 5-Methyl-N-(4-trifluoromethylphenyl)-6-(4-(trifluoromethyl)quinolin-7-  
 yl)pyrimidin-4-amine 852062-61-4P 852062-66-9P  
 852062-68-1P, 5-Methyl-6-(1-methyl-1H-benzimidazol-5-yl)-N-(4-  
 trifluoromethylphenyl)pyrimidin-4-amine 852062-69-2P,  
 6-(1H-Benzimidazol-6-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine  
 852063-00-4P, 6-(Quinoxalin-6-yl)-N-(4-  
 trifluoromethylphenyl)pyrimidin-4-amine 852063-01-5P,  
 5-Methyl-6-(quinoxalin-6-yl)-N-(4-trifluoromethylphenyl)pyrimidin-4-amine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of quinoxazolines and related derivs. vanilloid-1 receptor  
 antagonists for treating pain)


RN 851984-86-6 CAPLUS

CN 4-Pyrimidinamine, 6-(8-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA  
 INDEX NAME)



RN 851984-90-2 CAPLUS


CN 4-Pyrimidinamine, 6-(7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA  
 INDEX NAME)



RN 851984-98-0 CAPLUS


CN 4-Pyrimidinamine, 5-methyl-6-(7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-  
 (CA INDEX NAME)

10/817,328




RN 851985-02-9 CAPLUS

CN 4-Pyrimidinamine, 2-methyl-6-(7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-  
(CA INDEX NAME)




RN 851985-03-0 CAPLUS

CN 4-Pyrimidinamine, 6-(3-methyl-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-  
(CA INDEX NAME)



RN 851985-04-1 CAPLUS


CN 4-Pyrimidinamine, 6-(5-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA  
INDEX NAME)



RN 851985-06-3 CAPLUS


CN 4-Pyrimidinamine, 6-(6-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA  
INDEX NAME)

10/817,328




RN 851985-07-4 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methyl-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-  
(CA INDEX NAME)




RN 851985-08-5 CAPLUS

CN 4-Pyrimidinamine, 6-(6-fluoro-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-  
(CA INDEX NAME)




RN 851985-10-9 CAPLUS

CN 4-Pyrimidinamine, 6-(8-fluoro-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-  
(CA INDEX NAME)



RN 851985-12-1 CAPLUS

CN 4-Pyrimidinamine, N-[4-(trifluoromethyl)phenyl]-6-[6-(trifluoromethyl)-7-  
quinolinyl]- (CA INDEX NAME)




RN 851985-14-3 CAPLUS

CN 4-Pyrimidinamine, 6-(8-methyl-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-


10/817,328

(CA INDEX NAME)




RN 851985-18-7 CAPLUS

CN 4-Pyrimidinamine, 6-(7-isoquinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 851985-30-3 CAPLUS

CN 4-Pyrimidinamine, 6-(8-fluoro-7-quinolinyl)-5-methyl-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851985-33-6 CAPLUS


CN 4-Pyrimidinamine, 2-methyl-6-(8-methyl-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 851985-36-9 CAPLUS


CN 4-Pyrimidinamine, 5-methyl-6-(8-methyl-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)

10/817,328




RN 851985-53-0 CAPLUS

CN 4-Pyrimidinamine, 6-(6-fluoro-7-quinolinyl)-5-methyl-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 852062-40-9 CAPLUS

CN 4-Pyrimidinamine, 6-(8-ethyl-7-quinolinyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 852062-42-1 CAPLUS


CN 4-Pyrimidinamine, 6-(8-ethyl-7-quinolinyl)-5-methyl-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 852062-44-3 CAPLUS


CN 4-Pyrimidinamine, N-[2-fluoro-4-(trifluoromethyl)phenyl]-5-methyl-6-(7-quinolinyl)- (CA INDEX NAME)

10/817,328




RN 852062-51-2 CAPLUS

CN 4-Pyrimidinamine, 6-(1,8-naphthyridin-2-yl)-N-[4-(trifluoromethyl)phenyl]-  
(CA INDEX NAME)




RN 852062-52-3 CAPLUS

CN 4-Pyrimidinamine, 5-methyl-6-(8-quinolinyl)-N-[4-(trifluoromethyl)phenyl]-  
(CA INDEX NAME)



RN 852062-54-5 CAPLUS


CN 4-Pyrimidinamine, N-[4-(trifluoromethyl)phenyl]-6-[4-(trifluoromethyl)-7-quinolinyl]-  
(CA INDEX NAME)



RN 852062-55-6 CAPLUS


CN 4-Pyrimidinamine, 5-methyl-N-[4-(trifluoromethyl)phenyl]-6-[4-(trifluoromethyl)-7-quinolinyl]-  
(CA INDEX NAME)

10/817,328




RN 852062-61-4 CAPLUS

CN 4-Pyrimidinamine, 5-methyl-6-(1,8-naphthyridin-2-yl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 852062-66-9 CAPLUS

CN 4-Pyrimidinamine, 5-methyl-6-(1,5-naphthyridin-3-yl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 852062-68-1 CAPLUS


CN 4-Pyrimidinamine, 5-methyl-6-(1-methyl-1H-benzimidazol-5-yl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 852062-69-2 CAPLUS

CN 4-Pyrimidinamine, 6-(1H-benzimidazol-6-yl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)


10/817,328



RN 852063-00-4 CAPLUS  
CN 4-Pyrimidinamine, 6-(6-quinoxalinylyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 852063-01-5 CAPLUS  
CN 4-Pyrimidinamine, 5-methyl-6-(6-quinoxalinylyl)-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



IT 852062-03-4, N-(4-Trifluoromethylphenyl)-6-[1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-benzimidazol-5-yl]pyrimidin-4-amine  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of quinoxazolines and related derivs. vanilloid-1 receptor antagonists for treating pain)

RN 852062-03-4 CAPLUS  
CN 4-Pyrimidinamine, N-[4-(trifluoromethyl)phenyl]-6-[1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-benzimidazol-5-yl]- (CA INDEX NAME)




IT 852062-02-3P, N-(4-Trifluoromethylphenyl)-6-[1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-benzimidazol-6-yl]pyrimidin-4-amine  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of quinoxazolines and related derivs. vanilloid-1 receptor antagonists for treating pain)

RN 852062-02-3 CAPLUS



10/817,328


CN 4-Pyrimidinamine, N-[4-(trifluoromethyl)phenyl]-6-[1-[[2-(trimethylsilyl)ethoxy)methyl]-1H-benzimidazol-6-yl]- (CA INDEX NAME)




OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)  
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/817,328

L4 ANSWER 17 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 2005:436088 CAPLUS  
DN 143:133336  
TI Novel and Efficient Access to Phenylamino-pyrimidine Type Protein Kinase C  
Inhibitors Utilizing a Negishi Cross-Coupling Strategy  
AU Stanetty, Peter; Hattinger, Gregor; Schnuerch, Michael; Mihovilovic, Marko  
D.  
CS Institute of Applied Synthetic Chemistry, Vienna University of Technology,  
Vienna, A-1060, Austria  
SO Journal of Organic Chemistry (2005), 70(13), 5215-5220  
CODEN: JOCEAH; ISSN: 0022-3263  
PB American Chemical Society  
DT Journal  
LA English  
OS CASREACT 143:133336  
IT 858351-89-0P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of 3-{4-[2-(3-chlorophenylamino)pyrimidin-4-yl]pyridin-2-  
ylamino}propanol and analogs via Negishi-type cross-coupling reaction  
and subsequent nucleophilic substitution reactions)  
RN 858351-89-0 CAPLUS  
CN 4-Pyrimidinamine, 6-(2-fluoro-4-pyridinyl)-N-[3-(trifluoromethyl)phenyl]-  
(CA INDEX NAME)



IT 858351-92-5P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of 3-{4-[2-(3-chlorophenylamino)pyrimidin-4-yl]pyridin-2-  
ylamino}propanol and analogs via Negishi-type cross-coupling reaction  
and subsequent nucleophilic substitution reactions)  
RN 858351-92-5 CAPLUS  
CN 1-Propanol, 3-[[4-[6-[[3-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]-2-  
pyridinyl]amino]- (CA INDEX NAME)



OSC.G 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)  
RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/817,328

L4 ANSWER 18 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 2005:324144 CAPLUS  
DN 142:392431  
TI Pyrimidinylarylamines and pyrimidinylaryl benzamides as protein kinase  
inhibitors and their preparation  
IN Chopiuk, Greg; Furet, Pascal; Gray, Nathanael Schiander; Imbach, Patricia;  
Liu, Yi; Schoepfer, Joseph; Steensma, Ruo  
PA IRM LLC, Bermuda  
SO PCT Int. Appl., 39 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005033086	A1	20050414	WO 2004-US32473	20040930
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004278413	A1	20050414	AU 2004-278413	20040930
	AU 2004278413	B2	20080731		
	CA 2539339	A1	20050414	CA 2004-2539339	20040930
	US 20050171105	A1	20050804	US 2004-956412	20040930
	US 7189729	B2	20070313		
	EP 1670771	A1	20060621	EP 2004-789483	20040930
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004014930	A	20061107	BR 2004-14930	20040930
	CN 1860106	A	20061108	CN 2004-80028450	20040930
	CN 100412066	C	20080820		
	JP 2007507531	T	20070329	JP 2006-534171	20040930
	MX 2006003557	A	20060620	MX 2006-3557	20060330
	IN 2006CN01095	A	20070817	IN 2006-CN1095	20060330
PRAI	US 2003-507592P	P	20030930		
	WO 2004-US32473	W	20040930		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 142:392431; MARPAT 142:392431

IT 850087-67-1P, N-[3-[[2-[6-(4-Trifluoromethylphenylamino)pyrimidin-4-yl]phenyl]amino]phenyl]benzamide  
850087-68-2P, 4-(4-Methylpiperazin-1-ylmethyl)-N-[3-[[2-[6-(4-Trifluoromethylphenylamino)pyrimidin-4-yl]phenyl]amino]phenyl]benzamide  
850087-75-1P, N-Cyclopropyl-3-[[2-[6-(4-Trifluoromethylphenylamino)pyrimidin-4-yl]phenyl]amino]benzamide  
850087-76-2P, [6-[2-(3-Fluorophenylamino)phenyl]pyrimidin-4-yl](4-Trifluoromethylphenyl)amine 850087-77-3P, [6-[2-(2-Fluorophenylamino)phenyl]pyrimidin-4-yl](4-Trifluoromethylphenyl)amine 850087-78-4P, [6-[2-(4-Fluorophenylamino)phenyl]pyrimidin-4-yl](4-Trifluoromethylphenyl)amine 850087-79-5P, [6-[2-(2-Chlorophenylamino)phenyl]pyrimidin-4-yl](4-Trifluoromethylphenyl)amine 850087-80-8P, [6-[2-(3-Chlorophenylamino)phenyl]pyrimidin-4-yl](4-


10/817,328

trifluoromethylphenyl)amine 850087-81-9P,  
[6-[2-(4-Chlorophenylamino)phenyl]pyrimidin-4-yl](4-  
trifluoromethylphenyl)amine 850087-82-0P,  
[6-(2-o-Tolylaminophenyl)pyrimidin-4-yl](4-trifluoromethylphenyl)amine  
850087-83-1P, [6-(2-m-Tolylaminophenyl)pyrimidin-4-yl](4-  
trifluoromethylphenyl)amine 850087-84-2P,  
[6-(2-p-Tolylaminophenyl)pyrimidin-4-yl](4-trifluoromethylphenyl)amine  
850087-85-3P, 3-[[2-[6-(4-Trifluoromethylphenylamino)pyrimidin-4-  
yl]phenyl]amino]benzaldehyde 850087-86-4P,  
4-[[2-[6-(4-Trifluoromethylphenylamino)pyrimidin-4-  
yl]phenyl]amino]benzaldehyde 850087-87-5P,  
(4-Trifluoromethylphenyl)[6-[2-(2-  
trifluoromethylphenylamino)phenyl]pyrimidin-4-yl]amine  
850087-88-6P, (4-Trifluoromethylphenyl)[6-[2-(4-  
trifluoromethylphenylamino)phenyl]pyrimidin-4-yl]amine  
850087-89-7P, N,N-Dimethyl-N'-[2-[6-(4-  
trifluoromethylphenylamino)pyrimidin-4-yl]phenyl]benzene-1,4-diamine  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(drug candidate; preparation of pyrimidine-containing arylamines and aryl  
benzamides as protein kinase inhibitors)


RN 850087-67-1 CAPLUS

CN Benzamide, N-[3-[[2-[6-[[4-(trifluoromethyl)phenyl]amino]-4-  
pyrimidinyl]phenyl]amino]phenyl]- (CA INDEX NAME)



RN 850087-68-2 CAPLUS


CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[3-[[2-[6-[[4-  
(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]phenyl]amino]phenyl]- (CA  
INDEX NAME)



Me


RN 850087-75-1 CAPLUS

CN Benzamide, N-cyclopropyl-3-[[2-[6-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]phenyl]amino]- (CA INDEX NAME)




RN 850087-76-2 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[(3-fluorophenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 850087-77-3 CAPLUS


CN 4-Pyrimidinamine, 6-[2-[(2-fluorophenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



10/817,328


RN 850087-78-4 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[(4-fluorophenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 850087-79-5 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[(2-chlorophenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 850087-80-8 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[(3-chlorophenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 850087-81-9 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[(4-chlorophenyl)amino]phenyl]-N-[4-


10/817,328

(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 850087-82-0 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[(2-methylphenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 850087-83-1 CAPLUS


CN 4-Pyrimidinamine, 6-[2-[(3-methylphenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 850087-84-2 CAPLUS


CN 4-Pyrimidinamine, 6-[2-[(4-methylphenyl)amino]phenyl]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)

10/817,328




RN 850087-85-3 CAPLUS

CN Benzaldehyde, 3-[[2-[6-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]phenyl]amino]- (CA INDEX NAME)



RN 850087-86-4 CAPLUS

CN Benzaldehyde, 4-[[2-[6-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]phenyl]amino]- (CA INDEX NAME)




RN 850087-87-5 CAPLUS

CN 4-Pyrimidinamine, N-[4-(trifluoromethyl)phenyl]-6-[2-[[2-(trifluoromethyl)phenyl]amino]phenyl]- (CA INDEX NAME)




10/817,328




RN 850087-88-6 CAPLUS

CN 4-Pyrimidinamine, N-[4-(trifluoromethyl)phenyl]-6-[2-[[4-(trifluoromethyl)phenyl]amino]phenyl]- (CA INDEX NAME)



RN 850087-89-7 CAPLUS

CN 1,4-Benzenediamine, N1,N1-dimethyl-N4-[2-[6-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)  
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

10/817,328

ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/817,328

L4 ANSWER 19 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 2005:260034 CAPLUS  
DN 142:336376  
TI Preparation of pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases  
IN Choidas, Axel; Backes, Alexander; Cotten, Matt; Engkvist, Ola; Felber, Beatrice; Freisleben, Achim; Godl, Klaus; Greff, Zoltan; Habenberger, Peter; Hafenbradl, Doris; Hartung, Christian; Herget, Thomas; Hoppe, Edmund; Klebl, Bert; Missio, Andrea; Mueller, Gerhard; Schwab, Wilfried; Zech, Birgit; Bravo, Jose; Harris, John; Le, Joelle; Macritchie, Jackie; Savic, Vladimir; Sherborne, Brad; Simpson, Don; Simpson, Don  
PA Axxima Pharmaceuticals AG, Germany  
SO PCT Int. Appl., 211 pp.  
CODEN: PIXXD2

DT Patent  
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005026129	A1	20050324	WO 2004-EP10353	20040915
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1678147	A1	20060712	EP 2004-786953	20040915
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	US 20070191344	A1	20070816	US 2006-572043	20061212
PRAI	EP 2003-20888	A	20030915		
	US 2003-504527P	P	20030922		
	EP 2004-10308	A	20040430		
	US 2004-569806P	P	20040512		
	WO 2004-EP10353	W	20040915		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 142:336376; MARPAT 142:336376


IT 848636-35-1P, N-[6-(2-Methoxyphenyl)pyrimidin-4-yl]benzene-1,4-diamine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(drug candidate; preparation of 4,6-disubstituted aminopyrimidines as modulators of protein kinases)


RN 848636-35-1 CAPLUS

CN 1,4-Benzenediamine, N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (CA INDEX NAME)


10/817,328



IT 848637-36-5P, N-[6-(2-Methoxyphenyl)pyrimidin-4-yl]-2-methylbenzene-1,4-diamine 848637-37-6P, N-[6-(2-Methoxyphenyl)pyrimidin-4-yl]benzene-1,3-diamine 848637-64-9P, N-[6-(2-Methoxyphenyl)-5-methylpyrimidin-4-yl]benzene-1,4-diamine 848638-16-4P, N-[6-(2-Methoxyphenyl)-2-methylpyrimidin-4-yl]benzene-1,4-diamine 848638-17-5P, N-[6-(4-Methoxyphenyl)-2-methylpyrimidin-4-yl]benzene-1,4-diamine 848638-99-3P, N-[6-(4-Methoxyphenyl)-5-methylpyrimidin-4-yl]benzene-1,4-amine 848639-00-9P, N-[6-(3-Aminophenyl)-5-methylpyrimidin-4-yl]benzene-1,4-amine 848639-90-7P, 4-Chloro-N-[6-(2-methoxyphenyl)pyrimidin-4-yl]benzene-1,3-diamine  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(drug candidate; preparation of 4,6-disubstituted aminopyrimidines as modulators of protein kinases)  
RN 848637-36-5 CAPLUS  
CN 1,4-Benzenediamine, N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]-2-methyl- (CA INDEX NAME)




RN 848637-37-6 CAPLUS  
CN 1,3-Benzenediamine, N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 848637-64-9 CAPLUS  
CN 1,4-Benzenediamine, N1-[6-(2-methoxyphenyl)-5-methyl-4-pyrimidinyl]- (CA INDEX NAME)


10/817,328




RN 848638-16-4 CAPLUS  
CN 1,4-Benzenediamine, N1-[6-(2-methoxyphenyl)-2-methyl-4-pyrimidinyl]- (CA  
INDEX NAME)




RN 848638-17-5 CAPLUS  
CN 1,4-Benzenediamine, N1-[6-(4-methoxyphenyl)-2-methyl-4-pyrimidinyl]- (CA  
INDEX NAME)



RN 848638-99-3 CAPLUS  
CN 1,4-Benzenediamine, N1-[6-(4-methoxyphenyl)-5-methyl-4-pyrimidinyl]- (CA  
INDEX NAME)




RN 848639-00-9 CAPLUS  
CN 1,4-Benzenediamine, N1-[6-(3-aminophenyl)-5-methyl-4-pyrimidinyl]- (CA  
INDEX NAME)



10/817,328

RN 848639-90-7 CAPLUS

CN 1,3-Benzenediamine, 4-chloro-N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]- (CA INDEX NAME)



IT 848640-02-8, N-[6-(2-Methoxyphenyl)pyrimidin-4-yl]-4-methylbenzene-1,3-diamine 848640-03-9,


[3-[6-(3-Amino-4-methylphenylamino)pyrimidin-4-yl]phenyl]carbamic acid 9H-fluoren-9-ylmethyl ester

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 4,6-disubstituted aminopyrimidines as modulators of protein kinases)

RN 848640-02-8 CAPLUS


CN 1,3-Benzenediamine, N1-[6-(2-methoxyphenyl)-4-pyrimidinyl]-4-methyl- (CA INDEX NAME)



RN 848640-03-9 CAPLUS

CN Carbamic acid, [3-[6-[(3-amino-4-methylphenyl)amino]-4-pyrimidinyl]phenyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

10/817,328



OSC.G	9	THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
RE.CNT	8	THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT		


10/817,328

L4 ANSWER 20 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 2005:99484 CAPLUS  
DN 142:198089  
TI Preparation of azinyl aryl amines as vanilloid receptor ligands.  
IN Blum, Charles A.; Brielmann, Harry; Hodgetts, Kevin J.  
PA Neurogen Corporation, USA  
SO PCT Int. Appl., 89 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005009977	A1	20050203	WO 2004-US22820	20040715
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004259712	A1	20050203	AU 2004-259712	20040715
	CA 2531490	A1	20050203	CA 2004-2531490	20040715
	EP 1651619	A1	20060503	EP 2004-778364	20040715
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
	CN 1823048	A	20060823	CN 2004-80020429	20040715
	JP 2007523875	T	20070823	JP 2006-520349	20040715
	IN 2005DN05450	A	20070817	IN 2005-DN5450	20051125
	US 20060229308	A1	20061012	US 2006-564583	20060406
PRAI	US 2003-487405P	P	20030715		
	WO 2004-US22820	W	20040715		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 142:198089; MARPAT 142:198089  
IT 837382-73-7P 837382-95-3P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of azinyl aryl amines as vanilloid receptor ligands)  
RN 837382-73-7 CAPLUS  
CN 4-Pyrimidinamine, 6-(3-methoxyphenyl)-2,5-dimethyl-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 837382-95-3 CAPLUS  
CN 4-Pyrimidinamine, N-[3-bromo-4-(trifluoromethyl)phenyl]-6-(3-



10/817,328

methoxyphenyl)- (CA INDEX NAME)



OSC.G	4	THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/817,328

L4 ANSWER 21 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 2004:878265 CAPLUS  
DN 141:366255  
TI Preparation of substituted pyrimidinamines and triazinamines as protein  
kinase inhibitors  
IN Ding, Qiang; Sim, Tae-Bo; Zhang, Guobao; Adrian, Francisco; Gray,  
Nathanael S.; Schultz, Peter G.  
PA IRM LLC, Bermuda  
SO PCT Int. Appl., 54 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004089286	A2	20041021	WO 2004-US10083	20040402
	WO 2004089286	A3	20050421		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 20050014753	A1	20050120	US 2004-817328	20040401
	AU 2004227943	A1	20041021	AU 2004-227943	20040402
	AU 2004227943	B2	20080904		
	CA 2521184	A1	20041021	CA 2004-2521184	20040402
	EP 1613595	A2	20060111	EP 2004-758738	20040402
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
	BR 2004009173	A	20060411	BR 2004-9173	20040402
	CN 1798734	A	20060705	CN 2004-80015433	20040402
	JP 2006522143	T	20060928	JP 2006-509594	20040402
	MX 2005010711	A	20051215	MX 2005-10711	20051004
	IN 2005CN02515	A	20070831	IN 2005-CN2515	20051004
PRAI	US 2003-460838P	P	20030404		
	US 2004-817328	A	20040401		
	WO 2004-US10083	W	20040402		
OS	MARPAT 141:366255				
IT	714962-06-8P	778269-75-3P	778269-83-3P		
	778269-90-2P	778269-96-8P	778270-03-4P		
	778270-11-4P	778270-17-0P	778270-47-6P		
	778270-56-7P	778270-68-1P	778270-88-5P		
	778270-96-5P	778271-56-0P	778271-64-0P		
	778271-72-0P	778271-79-7P	778271-87-7P		
	778271-96-8P	778272-04-1P	778272-13-2P		
	778272-18-7P	778272-26-7P	778272-35-8P		
	778272-44-9P	778272-59-6P	778272-66-5P		
	778272-73-4P	778272-97-2P	778273-04-4P		
	778273-14-6P	778273-19-1P	778273-25-9P		
	778273-32-8P	778273-36-2P	778273-43-1P		
	778273-48-6P	778273-56-6P	778273-63-5P		
	778273-70-4P	778273-75-9P	778273-82-8P		
	778273-90-8P	778274-04-7P	778274-14-9P		
	778274-20-7P	778274-28-5P	778274-34-3P		

10/817,328


778274-38-7P	778274-42-3P	778274-49-0P
778274-58-1P	778274-65-0P	778274-74-1P
778274-81-0P	778274-89-8P	778274-97-8P
778275-02-8P	778275-08-4P	778275-15-3P
778275-21-1P	778275-31-3P	778275-36-8P
778275-45-9P	778275-51-7P	778275-58-4P
778275-64-2P	778275-72-2P	778275-78-8P
778275-86-8P	778275-92-6P	778276-06-5P
778276-12-3P	778276-24-7P	778276-30-5P
778276-36-1P	778276-42-9P	778276-48-5P
778276-64-5P	778276-70-3P	778276-77-0P
778276-83-8P	778276-89-4P	778276-94-1P
778276-99-6P	778277-07-9P	778277-15-9P
778277-22-8P	778277-24-0P	778277-31-9P
778277-37-5P	778277-44-4P	778277-49-9P
778277-54-6P	778277-62-6P	778277-67-1P
778277-74-0P	778279-08-6P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted pyrimidinamines and triazinamines as protein kinase inhibitors for treating tumors)


RN 714962-06-8 CAPLUS

CN Benzenesulfonamide, 4-methoxy-N-[3-[6-[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl)- (CA INDEX NAME)




RN 778269-75-3 CAPLUS

CN Benzamide, N,N-dimethyl-4-[6-[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl)- (CA INDEX NAME)



RN 778269-83-3 CAPLUS


CN Benzamide, N-[2-(4-morpholinyl)ethyl]-4-[6-[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl)- (CA INDEX NAME)



RN 778269-90-2 CAPLUS


10/817,328

CN 4-Pyrimidinamine, 6-(4-pyridinyl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 778269-96-8 CAPLUS

CN 4-Pyrimidinamine, 6-(1,4-dioxo-8-azaspiro[4.5]dec-8-yl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 778270-03-4 CAPLUS

CN 4-Pyrimidinamine, 6-[3-(methylsulfonyl)phenyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 778270-11-4 CAPLUS

CN Benzamide, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778270-17-0 CAPLUS


CN 4-Pyrimidinamine, 6-(3-aminophenyl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 778270-47-6 CAPLUS

10/817,328


CN 4-Pyrimidinamine, 6-(1H-imidazol-1-yl)-N-[4-(trifluoromethoxy)phenyl]-  
(CA INDEX NAME)




RN 778270-56-7 CAPLUS  
CN 4-Pyrimidinamine, 6-[2-[[3-(1H-imidazol-1-yl)propyl]amino]-4-pyridinyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 778270-68-1 CAPLUS  
CN Benzenesulfonamide, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778270-88-5 CAPLUS  
CN Benzamide, N-(2-hydroxyethyl)-4-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-2-pyridinyl]- (CA INDEX NAME)




RN 778270-96-5 CAPLUS  
CN 4-Pyrimidinamine, 6-(4-morpholinyl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)


10/817,328




RN 778271-56-0 CAPLUS  
CN 2-Pyrrolidinemethanol, 1-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778271-64-0 CAPLUS  
CN 4-Pyrimidinamine, 6-(1,3-benzodioxol-5-yl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 778271-72-0 CAPLUS  
CN 4-Pyrimidinamine, 6-(3-methoxyphenyl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 778271-79-7 CAPLUS  
CN Benzenemethanol, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778271-87-7 CAPLUS  
CN 4-Pyrimidinamine, 6-(1-piperazinyl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)


10/817,328

INDEX NAME)




RN 778271-96-8 CAPLUS

CN 4-Pyrimidinamine, 6-(1-oxido-4-pyridinyl)-N-[4-(trifluoromethoxy)phenyl]-  
(CA INDEX NAME)




RN 778272-04-1 CAPLUS

CN 4-Pyrimidinamine, 6-(3-pyridinyl)-N-[4-(trifluoromethoxy)phenyl]- (CA  
INDEX NAME)




RN 778272-13-2 CAPLUS

CN 4-Pyrimidinamine, 6-(2-methyl-1H-imidazol-1-yl)-N-[4-  
(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 778272-18-7 CAPLUS


CN 4-Pyrimidinamine, 6-(5-methyl-1H-pyrazol-1-yl)-N-[4-  
(trifluoromethoxy)phenyl]- (CA INDEX NAME)



10/817,328


RN 778272-26-7 CAPLUS

CN 4-Pyrimidinamine, 6-(1H-benzimidazol-1-yl)-N-[4-(trifluoromethoxy)phenyl]-  
(CA INDEX NAME)




RN 778272-35-8 CAPLUS

CN 4-Pyrimidinamine, 6-(4-pyridinyl)-N-[4-(trifluoromethyl)phenyl]- (CA  
INDEX NAME)




RN 778272-44-9 CAPLUS

CN 4-Pyrimidinamine, N-methyl-6-(4-pyridinyl)-N-[4-(trifluoromethoxy)phenyl]-  
(CA INDEX NAME)




RN 778272-59-6 CAPLUS

CN 4-Pyrimidinamine, 2-methyl-6-(4-pyridinyl)-N-[4-(trifluoromethoxy)phenyl]-  
(CA INDEX NAME)



RN 778272-66-5 CAPLUS

CN 4-Pyrimidinamine, 5-methyl-6-(4-pyridinyl)-N-[4-(trifluoromethoxy)phenyl]-  
(CA INDEX NAME)




RN 778272-73-4 CAPLUS

CN 4-Pyrimidinamine, 6-(6-chloro-3-pyridinyl)-N-[4-(trifluoromethoxy)phenyl]-




10/817,328

(CA INDEX NAME)




RN 778272-97-2 CAPLUS

CN Ethanone, 1-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-1-piperazinyl]- (CA INDEX NAME)




RN 778273-04-4 CAPLUS

CN 4-Pyrimidinamine, 6-(2-pyrazinyl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 778273-14-6 CAPLUS

CN 4-Piperidinone, 1-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778273-19-1 CAPLUS


CN 4-Piperidinone, 1-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-, O-methyloxime (CA INDEX NAME)



RN 778273-25-9 CAPLUS


CN 4-Pyrimidinamine, 6-(2-chloro-4-pyridinyl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

10/817,328




RN 778273-32-8 CAPLUS

CN 1,3-Propanediamine, N1,N1-dimethyl-N3-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-2-pyridinyl]- (CA INDEX NAME)




RN 778273-36-2 CAPLUS

CN 1,3-Propanediamine, N1-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-2-pyridinyl]- (CA INDEX NAME)




RN 778273-43-1 CAPLUS

CN Ethanol, 2-[[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-2-pyridinyl]amino]- (CA INDEX NAME)



RN 778273-48-6 CAPLUS


CN 4-Morpholineethanamine, N-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-2-pyridinyl]- (CA INDEX NAME)



RN 778273-56-6 CAPLUS


CN 4-Pyrimidinamine, 6-[2-[(4-pyridinylmethyl)amino]-4-pyridinyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

10/817,328




RN 778273-63-5 CAPLUS

CN 4-Pyrimidinamine, 6-[2-[2-(dimethylamino)ethoxy]-4-pyridinyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 778273-70-4 CAPLUS

CN 4-Pyrimidinamine, 6-[2-(4-morpholinyl)-4-pyridinyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 778273-75-9 CAPLUS

CN 4-Pyrimidinamine, 6-[2-(1-piperazinyl)-4-pyridinyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 778273-82-8 CAPLUS


CN Ethanone, 1-[3-[6-[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)



RN 778273-90-8 CAPLUS


CN Acetamide, N-[3-[6-[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)

10/817,328




RN 778274-04-7 CAPLUS

CN Benzamide, N-(1-methylethyl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778274-14-9 CAPLUS

CN Benzamide, N-4-morpholinyl-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778274-20-7 CAPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778274-28-5 CAPLUS


CN Benzamide, N-(2-furanylmethyl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778274-34-3 CAPLUS


CN Methanone, 4-morpholinyl[3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)

10/817,328



RN 778274-38-7 CAPLUS


CN Methanone, (4-ethyl-1-piperazinyl) [3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)



RN 778274-42-3 CAPLUS


CN Methanone, [(2S)-2-(hydroxymethyl)-1-pyrrolidinyl] [3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 778274-49-0 CAPLUS

CN Benzamide, N-[(tetrahydro-2-furanyl)methyl]-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778274-58-1 CAPLUS

CN Benzamide, N-(3-pyridinylmethyl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778274-65-0 CAPLUS

CN 3-Piperidinecarboxamide, N,N-diethyl-1-[3-[6-[[4-


10/817,328

(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzoyl]- (CA INDEX NAME)




RN 778274-74-1 CAPLUS

CN Benzamide, N-[4-(dimethylamino)phenyl]-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778274-81-0 CAPLUS


CN Benzamide, 4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778274-89-8 CAPLUS

CN Methanone, [(2R)-2-(hydroxymethyl)-1-pyrrolidinyl][3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 778274-97-8 CAPLUS


CN Benzamide, N-(2-hydroxyethyl)-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)

10/817,328




RN 778275-02-8 CAPLUS

CN Benzamide, N-[2-(dimethylamino)ethyl]-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778275-08-4 CAPLUS


CN Benzamide, N-[3-(aminocarbonyl)phenyl]-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778275-15-3 CAPLUS

CN Methanone, [(2S)-2-(hydroxymethyl)-1-pyrrolidinyl][4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 778275-21-1 CAPLUS

CN Methanone, [(2R)-2-(hydroxymethyl)-1-pyrrolidinyl][4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.

10/817,328




RN 778275-31-3 CAPLUS

CN Methanone, 4-morpholinyl[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 778275-36-8 CAPLUS

CN Benzamide, N-4-morpholinyl-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778275-45-9 CAPLUS

CN Benzamide, N-[3-(1H-imidazol-1-yl)propyl]-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778275-51-7 CAPLUS

CN 3-Piperidinecarboxamide, 1-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




10/817,328




RN 778275-58-4 CAPLUS

CN Benzamide, 2-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778275-64-2 CAPLUS

CN Methanone, [3-amino-5-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]-4-morpholinyl- (CA INDEX NAME)



RN 778275-72-2 CAPLUS


CN 4-Pyrimidinamine, 6-(2-aminophenyl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 778275-78-8 CAPLUS


CN Benzamide, 4-[5-methyl-6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)

10/817,328




RN 778275-86-8 CAPLUS

CN Methanone, [4-methyl-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]-4-morpholinyl- (CA INDEX NAME)




RN 778275-92-6 CAPLUS

CN Benzamide, N-(2-hydroxyethyl)-4-methyl-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778276-06-5 CAPLUS


CN Methanone, [3-amino-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]-4-morpholinyl- (CA INDEX NAME)



RN 778276-12-3 CAPLUS


CN Benzamide, 3-amino-N-(2-hydroxyethyl)-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)

10/817,328




RN 778276-24-7 CAPLUS

CN Benzenesulfonamide, 4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778276-30-5 CAPLUS

CN 4-Pyrimidinamine, 6-[3-(4-morpholinylsulfonyl)phenyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 778276-36-1 CAPLUS

CN 4-Pyrimidinamine, 6-[4-(4-morpholinylsulfonyl)phenyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 778276-42-9 CAPLUS


CN Benzamide, N-(2,6-dichlorophenyl)-4-[6-[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



10/817,328


RN 778276-48-5 CAPLUS

CN 3-Piperidinecarboxamide, 1-[3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzoyl]- (CA INDEX NAME)




RN 778276-64-5 CAPLUS

CN Benzamide, 3-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-2-pyridinyl]- (CA INDEX NAME)




RN 778276-70-3 CAPLUS

CN 4-Pyrimidinamine, 6-[2-(2-aminophenyl)-4-pyridinyl]-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 778276-77-0 CAPLUS


CN Benzamide, 2-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-2-pyridinyl]- (CA INDEX NAME)



RN 778276-83-8 CAPLUS


CN Benzamide, 4-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-2-pyridinyl]- (CA INDEX NAME)

10/817,328




RN 778276-89-4 CAPLUS

CN Benzamide, 3-[6-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778276-94-1 CAPLUS

CN Benzamide, 4-[6-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778276-99-6 CAPLUS

CN Benzamide, N-[2-(4-morpholinyl)ethyl]-4-[6-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778277-07-9 CAPLUS


CN Benzamide, N-[2-(4-morpholinyl)ethyl]-4-[4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-2-pyridinyl]- (CA INDEX NAME)



10/817,328


RN 778277-15-9 CAPLUS

CN Benzamide, N-(2-hydroxyethyl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778277-22-8 CAPLUS

CN Benzamide, N-(4-pyridinylmethyl)-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778277-24-0 CAPLUS

CN Benzamide, N-[3-(1H-imidazol-1-yl)propyl]-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778277-31-9 CAPLUS

CN Methanone, [4-(2-hydroxyethyl)-1-piperazinyl][3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)



RN 778277-37-5 CAPLUS


CN Benzamide, N-methyl-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



10/817,328


RN 778277-44-4 CAPLUS

CN 1-Naphthalenecarboxaldehyde, 4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778277-49-9 CAPLUS

CN 2-Thiophenecarboxaldehyde, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778277-54-6 CAPLUS

CN Benzamide, 3-amino-N-methyl-5-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 778277-62-6 CAPLUS


CN Benzamide, 2-fluoro-N-(2-hydroxyethyl)-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



10/817,328


RN 778277-67-1 CAPLUS

CN Benzamide, 2-cyano-N-methyl-4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 778277-74-0 CAPLUS

CN 4-Pyrimidinamine, 6-(5-quinolinyl)-N-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 778279-08-6 CAPLUS

CN Benzamide, N-[2-(4-morpholinyl)ethyl]-3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




IT 778278-85-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of substituted pyrimidinamines and triazinamines as protein kinase inhibitors for treating tumors)

RN 778278-85-6 CAPLUS

CN Benzoic acid, 4-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



OSC.G 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT



10/817,328

10/817,328

L4 ANSWER 22 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 2004:857162 CAPLUS  
DN 141:350185  
TI Preparation of pyrimidine derivatives with lysophosphatidic acid  
acyltransferase  $\beta$  (LPAAT- $\beta$ ) inhibitory activity  
IN Bhatt, Rama; Gong, Baoqing; Hong, Feng; Jenkins, Scott A.; Klein, J.  
Peter; Kohm, Cory T.; Tulinsky, John  
PA Cell Therapeutics, Inc., USA  
SO U.S. Pat. Appl. Publ., 80 pp., which  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20040204386	A1	20041014	US 2003-671070	20030924
	US 7419984	B2	20080902		
	US 20090099183	A1	20090416	US 2008-194192	20080819
PRAI	US 2002-419694P	P	20021017		
	US 2003-460776P	P	20030404		
	US 2003-671070	A1	20030924		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 141:350185; MARPAT 141:350185


IT 774607-65-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of pyrimidine derivs. with lysophosphatidic acid  
acyltransferase  $\beta$  (LPAAT- $\beta$ ) inhibitory activity)

RN 774607-65-7 CAPLUS


CN 4-Pyrimidinamine, 6-[5-bromo-2-(methoxymethyl)phenyl]-N-[4-  
(trifluoromethyl)phenyl]- (CA INDEX NAME)



OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)  
RE.CNT 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 23 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2004:550744 CAPLUS  
 DN 141:89118  
 TI Preparation of biaryl derivatives having differential tumor cytotoxicity  
 IN Chyba, Jason; Deveraux, Quinn; Hampton, Garret; King, Fred  
 PA IRM Llc, Bermuda  
 SO U.S. Pat. Appl. Publ., 11 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20040132786	A1	20040708	US 2003-739667	20031218
	US 7125997	B2	20061024		
	WO 2004058713	A1	20040715	WO 2003-US40686	20031218
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003299750	A1	20040722	AU 2003-299750	20031218
PRAI	US 2002-435853P	P	20021220		
	US 2003-491132P	P	20030729		
	WO 2003-US40686	W	20031218		
OS	MARPAT 141:89118				
IT	714962-05-7P, 3-[6-[(4-Trifluoromethoxyphenyl)amino]pyrimidin-4-yl]benzoic acid				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(intermediate; preparation of biaryl derivs. having differential tumor cytotoxicity as antitumor agents)				
RN	714962-05-7 CAPLUS				
CN	Benzoic acid, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-(CA INDEX NAME)				



IT 714962-03-5P, 3-[6-[(4-Trifluoromethoxyphenyl)amino]pyrimidin-4-yl]-N-(2-trifluoromethylbenzyl)benzamide 714962-06-8P, 4-Methoxy-N-[3-[6-[(4-trifluoromethoxyphenyl)amino]pyrimidin-4-yl]phenyl]benzenesulfonamide


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of biaryl derivs. having differential tumor cytotoxicity as antitumor agents)

RN 714962-03-5 CAPLUS


CN Benzamide, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-N-[[2-(trifluoromethyl)phenyl]methyl]-(CA INDEX NAME)

10/817,328



RN 714962-06-8 CAPLUS

CN Benzenesulfonamide, 4-methoxy-N-[3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]phenyl]- (CA INDEX NAME)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/817,328

L4 ANSWER 24 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN  
AN 1996:743723 CAPLUS  
DN 126:18874  
OREF 126:3921a,3924a  
TI Preparation of benzimidazoles as modulators of the GABAA receptor complex  
IN Teuber, Lene; Waetjen, Frank; Fukuda, Yoshimasa; Ushiroda, Osamu; Sasaki, Toshiro  
PA Neurosearch A/S, Den.; Meiji Seika Kaisha, Ltd.  
SO PCT Int. Appl., 55 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9633194	A1	19961024	WO 1996-EP1606	19960417
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
	CA 2218493	A1	19961024	CA 1996-2218493	19960417
	CA 2218493	C	20050222		
	AU 9656891	A	19961107	AU 1996-56891	19960417
	AU 695957	B2	19980827		
	EP 821684	A1	19980204	EP 1996-914932	19960417
	EP 821684	B1	20011205		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, LT, LV, FI				
	CN 1182427	A	19980520	CN 1996-193419	19960417
	CN 1072669	C	20011010		
	JP 11501320	T	19990202	JP 1996-531464	19960417
	JP 3342874	B2	20021111		
	HU 9801692	A2	19990329	HU 1998-1692	19960417
	HU 9801692	A3	20011128		
	RU 2135493	C1	19990827	RU 1997-119173	19960417
	BR 9608048	A	19991130	BR 1996-8048	19960417
	CZ 287545	B6	20001213	CZ 1997-3292	19960417
	AT 210132	T	20011215	AT 1996-914932	19960417
	EP 1164134	A1	20011219	EP 2001-112476	19960417
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	SK 282425	B6	20020107	SK 1997-1399	19960417
	PL 183853	B1	20020731	PL 1996-322892	19960417
	EE 4310	B1	20040615	EE 1997-283	19960417
	CA 2217601	A1	19961024	CA 1996-2217601	19960419
	CA 2217601	C	20020416		
	CN 1182426	A	19980520	CN 1996-193420	19960419
	AT 344257	T	20061115	AT 1996-912025	19960419
	NO 9704844	A	19971216	NO 1997-4844	19971020
	NO 314504	B1	20030331		
	US 5922724	A	19990713	US 1998-945023	19980205
	HK 1015674	A1	20021011	HK 1998-111156	19981009
PRAI	DK 1995-460	A	19950421		
	EP 1996-914932	A3	19960417		
	WO 1996-EP1606	W	19960417		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 126:18874

IT 184097-98-1P


10/817,328

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation of benzimidazoles as modulators of the GABAA receptor complex)

RN 184097-98-1 CAPLUS

CN 1,2-Benzenediamine, 4-(3-furanyl)-N1-[6-(1H-imidazol-1-yl)-4-pyrimidinyl]-  
(CA INDEX NAME)



OSC.G 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)  
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/817,328

L4 ANSWER 25 OF 25 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1986:478951 CAPLUS

DN 105:78951

OREF 105:12817a,12820a

TI Pyrimidine derivatives and their use

IN Takaya, Takao; Murata, Masayoshi; Ito, Kiyotaka

PA Fujisawa Pharmaceutical Co., Ltd. , Japan

SO Eur. Pat. Appl., 87 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 168262	A2	19860115	EP 1985-305004	19850712
	EP 168262	A3	19870513		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	US 4725600	A	19880216	US 1985-751867	19850705
	JP 61044872	A	19860304	JP 1985-154545	19850712
PRAI	GB 1984-17852	A	19840713		
	GB 1984-23667	A	19840919		
	GB 1984-30456	A	19841203		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 105:78951


IT 103555-19-7P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as cardiovascular agent and anticoagulant)

RN 103555-19-7 CAPLUS

CN 1,4-Benzenediamine, N1-[6-(3,4-dimethoxyphenyl)-2-methyl-4-pyrimidinyl]-  
(CA INDEX NAME)



OSC.G 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)

10/817,328

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

98.25

297.61

STN INTERNATIONAL LOGOFF AT 09:12:31 ON 25 NOV 2009